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Supplementary Figures 
Supplementary Figure 1  Quantile-Quantile plots and Manhattan plots of overall association results for pulse pressure 
(a,c) and mean arterial pressure (b,d). Quantile-Quantile plots show –log10(P) of association results. λGC before genomic 
control was 1.08 and 1.12. Manhattan plots show –log10(P) of association tests ordered by chromosome and position.  
a) 
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Supplementary Figure 2 Forest plots of the stage 1 meta-analysis for the 8 SNPs at the novel PP and/or MAP loci. Each of the SNPs included in the figure showed genome-wide significant 
association (P<5x10
-8
) with PP, MAP or both in data from stages 1 and 2 combined. The contributing effect from each study is shown by a blue square, with confidence intervals indicated 
by horizontal lines. The contributing weight of each study to the meta-analysis is indicated by the size of the square. The combined meta-analysis estimate in the stage 1 data is shown at 
the bottom of each graph. M: male subset, F: female subset. 
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Supplementary Figure 3 Expression levels of 6 genes in the novel PP-associated regions and 4 genes in the novel MAP-
associated regions measured in aorta tissue samples from 4 individuals  
Further details are given in the Supplementary Note.  
Cumulative (n=4) wiggle plots for a) PP and b) MAP associated gene transcripts are shown. PIK3CG expression was below 
the filtering threshold and is therefore not shown.  red: total reads per base.  blue: RefSeq intronic -and exonic regions.  
black:  Human mRNAs.  grey: Spliced ESTs.   
c) As positive controls, expression levels of 4 genes (Epidermal growth factor receptor (EGFR), actin alpha 2 (ACTA2), 
collagen type IV alpha 1 (COL4A1) and elastin (ELN)) expected to be expressed in aortic tissue were measured in the 
aorta samples described in the Supplementary Note.  Relative number of reads for each positive control gene transcript 
is presented as the log10 of the sum (n=4) of reads per kilo base per million.  
d) Relative number of reads for 6 PP and 4 MAP -associated gene transcripts are presented as the sum (n=4) of reads per 
kilo base per million (RpkM). PIK3CG expression was below the filtering threshold and was set to 0. GRB14 -and ADRB1 
transcripts were covered by reads located at only one or aberrant exonic -or intronic region and were therefore 
regarded as not expressed. 
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Supplementary Figure 4 Region plots of SNP association with ADRB1 and ZNF589 transcript expression. Statistical 
significance of each SNP is shown on the –log10 scale as a function of chromosome position (NCBI build 36). The 
correlations (r
2
) of each of the surrounding SNPs to SNP rs319684 are shown by the shade indicated in the key. Gene 
locations and orientation are indicated below the plot. Fine –scale recombination rate is shown in blue. 
a) Region plot of SNP association with ADRB1 transcript expression in brain and blood (PFC; pre-frontal cortex, VC; visual 
cortex). SNP rs2782980 is associated with MAP in this study. The P value of association of rs2782980 with ADRB1 is 
shown. The top eSNP for ADRB1 expression in brain or blood is rs740746 which has r
2
=0.125 with rs2782980 and shows 
association with MAP in our stage 1 analysis (P=8.9x10
-6
). The second most associated SNP is rs10787516 which has 
r
2
=0.092 and shows association with MAP in our stage 1 analysis (P=5.0x10
-4
). 
b) Region plot of SNP association with ZNF589 transcript expression in monocytes. SNP rs319684 is the best available 
proxy in this database for the MAP-associated SNP at the MAP4 locus rs319690 (r
2
=0.74). The P value of association of 
rs319684 with ZNF589 expression is shown. The top eSNP for ZNF589 expression in the region is rs1045482 which has 
r
2
=0.354 with rs319684. SNP rs6787599 which is in strong linkage disequilibrium with rs1045482 (r
2
=1) shows association 
with MAP in our stage 1 analysis (P=6.1x10
-4
). 
 
 
a) 
rs740746 (PFC) 
rs2782980 
P=3.2x10-9 (VC) 
rs10787516 (PFC) 
17 
 
 
 
b) 
rs319684  
P=1.2x10-13 
18 
 
Supplementary Tables 
Supplementary Table 1: Sample population characteristics and genotyping platform details for each study.  
A) Sample population characteristics. Stage 1: Age, Gene/Environment Susceptibility –Reykjavik (AGES) , Atherosclerosis Risk in Communities Study (ARIC), Austrian Stroke Prevention 
Study (ASPS), British 1958 Birth Cohort - Type 1 Diabetes Genetics Consortium (B58C-T1DGC), British 1958 Birth Cohort - Wellcome Trust Case Control Consortium (B58C-WTCCC), 
Baltimore Longitudinal Study of Ageing (BLSA), Busselton Health Study (BHS), Carlantino cohort (CARL), Cardiovascular Health Study (CHS), Cohorte Lausannoise (CoLaus), CROATIA-Vis, 
Diabetes Genetics Initiative controls only (DGI controls), Estonian Genome Project, University of Tartu (EGCUT), European Prospective Investigation of Cancer – Norfolk (EPIC Norfolk), ERF 
study, Fenland Study (Fenland),  Framingham Heart Study (FHS), Finland-United States Investigation of NIDDM Genetics (FUSION controls), INGI Friuli Venezia Giulia (INGI FVG) study, 
Invecchiare in Chianti (INCHIANTI), Kooperative Gesundheitsforschung in der Region Augsburg S3 (KORA S3), Micro-Isolates in South Tyrol (EUROSPAN) (MICROS), Myocardial Infarction 
Genetics Consortium (MIGen controls), Netherlands Study of Depression and Anxiety (NESDA), Northern Finland Birth Cohort of 1966 (NFBC1966), Northern Swedish Population Health 
Study (EUROSPAN) (NSPHS), Netherlands Twin Registry (NTR), Orkney Complex Disease Study (ORCADES), Precocious Coronary Artery Disease (PROCARDIS cntrols), Rotterdam Study I 
(RSI), Rotterdam Study II (RSII), Study of Health in Pomerania (SHIP), Supplemenation en Vitamines et Mineraux Antioxydants (SUVIMAX), TwinsUK, INGI Val Borbera, Stage 2: CROATIA-
Korcula, CROATIA-Split, Estonian Genome Project, University of Tartu (EGCUT+), Kooperative Gesundheitsforschung in der Region Augsburg F4 (KORA F4), LifeLines, LOndon LIfe Sciences 
POPulation (LOLIPOP_EW_A, LOLIPOP_EW_P, LOLIPOP_EW610), Lothian Birth Cohort 1921 (LBC1921), Lothian Birth Cohort (LBC1936), Multi-Ethnic Study of Atherosclerosis (MESA), 
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER/PHASE), Rotterdam Study III (RSIII), SardiNIA, Cardiovascular risk in Young Finns Study (YFS) and Women’s Genome Health 
Study (WGHS). 
cohorts n 
Age, years 
(s.d.) 
Gender 
(% f) 
PP mean 
(s.d.) 
MAP mean 
(s.d.) 
SBP mean 
(s.d.) 
DBP mean 
(s.d.) 
lambda 
PP (M/F) 
lambda 
MAP 
(M/F) %HTN 
%Hyp 
Ther BMI 
Stage 1                         
AGES 3195 51 58 49.1 (11.1) 100.1 (12.0) 132.2 (16.9) 83.4 (9.6) 1.03 1.05 34.9 6.4 25.2 (3.5) 
ARIC 9294 54.3 (5.7) 52 47.9 (12.9) 88.8 (12.0) 120.7 (18.0) 72.8 (10.4) 1.04 1.07 26.5 25.2 27.0 (4.8) 
ASPS 767 65 (8.1) 58 57.2(17.76) 107.7 (14.3) 143.3 (22.8) 87.4 (9.9) 1.01 1.01 66.4 25.2 26.7 (4.0) 
B58C-T1DGC 2580 44.3(0.3) 51 48.0 (8.5) 95.4 (11.7) 121.7 (15.3) 79.4 (10.5) 0.94/1.08 1.01/0.99 20.5 4.7 27.4 (4.9) 
B58C-WTCCC 1473 44.9(0.4) 50 47.8 (8.5) 95.5 (12.0) 126.7 (15.2) 79.1 (10.2) 0.99/0.99 1.01/1.00 17.4 4.2 27.4 (4.7) 
BLSA 701 42.4(13.2) 44 42.5 (10.9) 92.1 (11.6) 119.5 (15.0) 77.3 (10.2) 1.02/1.00 0.99/1.00 23.2 5.2 24.5 (3.6) 
BHS 1038 47.2(13.3) 58 46.9 (12.4) 92.0(12.2) 121.2 (15.2) 75.0 (9.9) 1.01/0.99 1.00/1.00 23.8 13.8 26.0 (4.2) 
CHS 3277 72.3 (5.39) 62 64.8 (18.5) 95.51 (14.2) 135 (21) 70 (11) 1.00 1.03 53 35 26.3 (4.4) 
CoLaus 4969 51.7(9.5) 53 48.7 (12.1) 97.3 (13.9) 127.3 (17.4) 79.4 (10.8) 1.01/1.00 0.99/1.00 33.9 16 25.8 (4.6) 
CROATIA-Vis 677 56.8 (15.6) 52 60.2 (27.5) 103.5 (13.8) 137.6 (24.5) 80.5 (11.5) 1.00 1.00 60.3 24.4 27.3 (4.3) 
DGI controls 1277 56.1 (8.7) 51 52.5 (14.2) 98.9 (11.2) 133.3 (18.4) 80.1 (10.0) 0.99/1.01 1.02/1.01 41.4 18 26.7 (3.8) 
EGCUT 1835 41.5 (16.4) 53 48.6 (14.2) 95 (13.4) 127.1 (19.3) 78.7 (12.2) 0.95 0.98 34.4 20.7 
26.0  
(5.4) 
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cohorts n 
Age, years 
(s.d.) 
Gender 
(% f) 
PP mean 
(s.d.) 
MAP mean 
(s.d.) 
SBP mean 
(s.d.) 
DBP mean 
(s.d.) 
lambda 
PP (M/F) 
lambda 
MAP 
(M/F) %HTN 
%Hyp 
Ther BMI 
EPIC Norfolk 2100 57.2 (7.8) 54 52.9 (10.6) 101.5 (13.8) 136.7 (19.1) 83.9 (11.9) 0.93/0.98 1.01/1.01 45.6 16 26.3 (3.9) 
ERF 2194 48.6 (14.5) 54 60.6 (16.7) 101.4 (13.4) 139.7 (20.8) 80.0 (10.00) 1.01 1.03 51.7 21.2 26.7 (4.7) 
Fenland 1401 45.0 (7.3) 56 47.2 (9.6) 91.3 (12.1) 122.8 (16.3) 75.5 (10.7) 0.99/1.00 1.01/1.00 18.8 5.5 27.1 (4.9) 
FHS 8096 38 (9) 54 43 (10) 91 (11) 119 (15) 77 (10) 1.05 1.06 17 5 25.9 (4.9) 
FUSION controls 1046 62.3 (6.8) 51 60.8 (16.3) 105.0(13.4) 139.4 (19.3) 81.5 (10.3) 0.99/1.01 0.98/1.01 51.8 21 27.1 (4.0) 
INCHIANTI 562 56.9(14.5) 55 58.1 (15.4) 103.0 (14.7) 138.4 (20.1) 81.4 (10.1) 1.00/1.00 1.00/1.00 59.6 23.7 27.1 (4.2) 
INGI CARL 476 50.2 64 51.9 (15.6) 97.7 (13.8) 128.6 (25.6) 78.8 (13.1) 0.96 1.02 39.2 21.5 26.3 (5.7) 
INGI FVG 617 51.5 59 52.1 (16.2) 102.7 (12.7) 137.3 (22.7) 85.6 (12.2) 0.99 0.99 58.4 21.9 25.0 (4.5) 
INGI Val Borbera 1580 53.7 (18.1) 57 53.1 (14.8) 95 (12.5) 131.8 (22.1) 78.6 (10.9) 1.02 0.97 40.5 26.6 25.8 (4.5) 
KORA S3 1644 52.5(10.1) 51 49.4 (13.0) 98.4 (11.8) 133.4 (18.5) 81.8 (10.9) 0.99/1.00 1.00/1.00 20.9 17 27.3 (4.1) 
MICROS 1078 45.3 (16.1) 57 53.4 (14.4) 98.1 (13.8) 132.9 (20.2) 79.9 (11.1) 0.99 0.98 36.8 7.6 25.6 (4.8) 
MIGen controls 1121 48.9(8.3) 38 47.4 (14) 97.1 (13.6) 127.1 (17.8) 80.2 (11.6) 1.00/1.00 0.99/1.01 36.4 13.4 27.1 (5.2) 
NESDA 1591 41.6 (12.4) 69 53.3 (12.2) 99.2 (13.5) 134.9 (19.4) 81.6 (11.5) 0.91/0.91 0.91/0.91 36.0 36.0 25.5 (4.9) 
NFBC1966 4761 31 52 47.5 (11.6) 93.0 (12.9) 125.2 (13.8) 77.5 (11.7) 0.97/0.90 1.01/1.03 21.7 2 24.6 (4.2) 
NSPHS 636 47.0 (20.7) 53 49.6 (15.6) 91.6 (11.7) 122.8 (18.7) 74.1 (7.9) 1.00 1.01 37.6 19.1 26.3 (4.8) 
NTR 241 36 (12) 66 46 (7) 89 (10) 122 (12) 74(10) 0.97 0.99 9.54 NA 25(4) 
ORCADES 693 53.6 (15.7) 54 55.0 (14.9) 95.7 (12.9) 130.2 (19.3) 76.3 (10.1) 0.98 0.98 41 21.9 27.8 (4.9) 
PROCARDIS 
controls 795 58.9 (6.9) 37 52.0 (13.5) 100.1 (11.9) 134.7 (18.6) 82.8 (10.0) 0.95/0.95 1.02/1.02 15 2 25.9 (3.7) 
RSI 4737 68 (8) 60 66 (18) 97 (14) 139 (22) 74 (11) 1.03 1.04 53 18 26.2 (3.6) 
RSII 1760 64 (7) 56 65 (17) 102 (13) 143 (21) 79 (11) 1.03 1.01 60 22 27.2 (4.2) 
SHIP 3306 45.0 (13.9) 53 50.47 (13.7) 101.9 (15.3) 133.1 (20.2) 83.5 (11.3) 0.98/0.99 1.01/1.00 40.9 16.3 26.9 (4.7) 
SUVIMAX 1673 50.5 (6.2) 60 43.0 (7.7) 92.4 (9.0) 120.9 (12.3) 78.0 (8.1) 1.00/1.00 1.00/1.00 19 0 23.5 (3.3) 
TwinsUK 873 45.8 (11.9) 100 44.8 (10.0) 93.2 (12.5) 122.9 (15.4) 78.2 (10.3) 0.99 1.00 27.3 22 24.8 (4.6) 
             Total Stage 1 74064                       
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cohorts n 
Age, years 
(s.d.) 
Gender 
(% f) 
PP mean 
(s.d.) 
MAP mean 
(s.d.) 
SBP mean 
(s.d.) 
DBP mean 
(s.d.) 
lambda 
PP (M/F) 
lambda 
MAP 
(M/F) %HTN 
%Hyp 
Ther BMI 
Stage 2                         
CROATIA-
Korcula 876 
 56.3 
(13.9) 64  58.5 (23.2)  104.1 (18.4)  143.1 (24.9)  84.6 (19.4)  1.03  1.08  51.4 28.6  27.3 (4.2) 
CROATIA-Split 498 49.0 (14.7) 57   52.2 (11.2) 96.2 (14.8)  130.9 (20.7)  78.7 (12.5)  0.99  0.99  35.4 21.5  26.9 (4.2) 
EGCUT+ 600 38.1 (15.8) 46.1 46.6 (12.6) 92.7 (11.3) 123.8 (17.1) 77.2 (10.0) 1.01 1.01 29.0 NA 
25.1 
(4.35) 
KORA F4 1709 60.6 (8.9) 52.2 53.53 (13.2) 104.1 (11.9) 124.8 (18.7) 76.3 (9.8) 1.01 1.00 35.2 34.5 28.0 (4.7) 
LifeLines 3202 54.9 (9.7) 60.5 55.7 (13.4) 96.7 (12.2) 133.8 (18.8) 78.1 (10.3) 0.99 1.00 39.5 18.7 26.7 (4.2) 
LOLIPOP_EW_A 878 53.3 (10.4) 23 53.1 (14.3) 101.1 (14.6) 136.5 (22.1) 83.4 (12.0) 0.99 0.99 47 25.6 27.9 (4.8) 
LOLIPOP_EW_P 725 55.9 (8.9) 0 56.6 (13.6) 104.2 (14.8) 141.9 (21.8) 85.3 (12.4) 1.00 0.99 56.6 31.8 28.6 (5.3) 
LOLIPOP_EW610 927 56.0 (9.8) 27 53.2 (13.4) 100.8 (13.8) 136.2 (20.9) 83.1 (11.3) 1.00 0.99 45.1 20 27.5 (4.7) 
LBC1921 376 69.0 (0.6) 64 88.4 (21.1) 116.7 (16.8) 175.6 (27.3) 87.2 (14.1) 0.99 0.99 91.8 34.6 26.2 (4.2) 
LBC1936 800 79.0 (0.8) 52  69.2 (15.2) 107.6 (13.0)  153.8 (20.3)  84.6 (11.1)  1.01 1.01 76.4 31.9 27.5 (4.3) 
MESA 2501 62.7 (10.3) 52 55.0 (17.5) 91.7 (14.5) 128.3 (23.7) 73.4 (11.6) 1.00 1.00 38.6 33.3 27.4 (5.1) 
PROSPER/PHASE 4535 75.3 (3.4) 55 75.0 (18.5) 116.5 (14.5) 166.4 (23.4) 91.5 (12.5) NA NA 65.3 73.2 26.8 (4.2) 
RSIII 2063 56.0 (5.8) 56 50.9 (12.9) 101.6 (14.4) 132.4 (18.7) 82.6 (10.8) 1.01 1.01 47.2 20.8 27.7 (4.7) 
SardiNIA 4305 43.6 (17.7) 56 48.6 (13.0) 93.3 (12.7) 125.7 (18.7) 77.1 (11.0) 1.10 1.11 14.1 11.6 25.3 (4.7) 
YFS 1987 37.7 (5.0) 54 45.3 (9.1) 91.6 (12.5) 121.8 (15.3) 76.5 (12.0) 1.01 1.01 6 7 26.0 (4.8) 
WGHS 22625 54.2 (7.1) 100.0% 47.6 (10.4) 93.8 (11.9) 125.5 (16.4) 78.0 (10.7) 1.09 1.07 24.7% 12.9% 25.9 (5.0) 
                          
Total Stage 2 48607                       
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B) Genotyping platforms, filters applied to SNPs and individuals (if any) before imputation, imputation software and genotype-phenotype association software are given. All individual 
study association results underwent genomic control before meta-analysis. Studies which used the short cut of PP and MAP effect sizes and standard errors are indicated in the last 
column.  
  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter    SBP  
(males/ 
Females) 
DBP  
(males/ 
Female
s) 
Stage 1                               
AGES Illumina 
370CNV 
Illumina 
BeadStudio 
>= 
95% 
>=0.97 >=10-6 >=0.
01 
none 325,094 MACH1 
v1.0.16 
36; v22 none PLINK and R 1.06 1.05 n 
ARIC Affymetrix 
6.0 
Birdseed >=95
% 
>=0.95 >=10-5 >=0.
01 
none 704,588 MACH1 
v1.0.16 
35; v21 none PLINK, 
MACH2QTL 
1.04 1.04 n 
ASPS Illumina 
Human610 
Beadstudio >=97.
5% 
>=0.98 >=10-6 >=0.
01 
none 550635 MACH1 
v1.0.15 
36; v22 none ProbABEL 1.02 1.02 n 
B58C-WTCCC Affymetrix 
500K 
CHIAMO >0.97 >0.95 
MAF>0.
05, 
>0.99 
MAF<0.
05 
5.70x10-
7 
none none 490,032 IMPUTE2 35; v21 none SNPTEST 1.02/1.0
1 
1.02/1.
00 
y 
B58C-T1DGC Illumina 
550K 
ILLUMINUS >0.98 none none none SNPs mapping 
to >1 locus in 
the genome 
539,548 MACH1 
V1.0.13 
35; v21 none ProbABEL v0.0-
5b 
1.00/1.0
0 
1.01/1.
00 
y 
BLSA Illumina 
550K 
Beadstudio >0.97 >0.99 >10-4 >0.0
1 
none 501,764 MACH1 
v1.0.15 
35; v21 r2hat 
<0.3, 
MAF < 
1% 
Merlin offline 1.04/1.0
1 
1.05/1.
03 
y 
BHS Illumina 
610-Quad 
chip 
Illumina 
BeadStudio 
>0.94 99% for 
SNPS 
with 
MAF<1
%, 95% 
for all 
other 
SNPs 
p<5.7x1
0-7 for 
all SNPs 
at 
imputati
on 
Non
e 
Monomorphic 
SNPs removed 
549,294 MACH1 36 none mach2qtl NA NA n 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
CHS Illumina 
370CNV 
BeadStudio >=97
% 
>0.95 >=10-5 none >2 replicate or 
Mendelian 
errors, 
heterozyg. freq. 
=0 
306,655 BIMBAM
103 v0.99 
36; v22 varianc
e of 
allele 
dosage 
< 0.005 
R 1.01 1.03 n 
CoLaus Affymetrix 
500K 
BRLMM >0.95 >0.70 >10-7 >0 none 390,631 IMPUTE2 
v0.2 
35; v21 none  custom C++ 0.99/0.9
9 
1.00/1.
01 
y 
CROATIA-Vis illumina 
318K 
Beadstudio >98% >98% 10-6 >0.0
1 
ethnic outliers, 
gender 
mismatches, 
duplicates, 
excess IBS, 
incompatible 
with the 
pedigree, excess 
heterozygosity 
275,093 MACH1 36 v22 none ProbABEL 1.07 0.99 n 
DGI cntrols Affymetrix 
500K 
BRLMM none >0.95 >10-6 in 
controls 
≥00
1 
SNPs mapping 
to >1 locus in 
the genome 
378,860 MACH1 
v1.0.9 
35; v21 none SNPTEST 1.01/1.0
1 
1.00/0.
99 
y 
EGCUT Illumina 
370CNV 
Illumina 
BeadStudio 
≥95% ≥98% 10-6 ≥0.
1 
Cryptic 
relatedness; 
Incomplete 
phenotpe 
information 
326,339 IMPUTE2 
v0.5.0 
36; v22 none SNPTEST 0.99 0.99 n 
EPIC Norfolk Affymetrix 
500K 
BRLMM ≥0.94 ≥0.90 >10-6 ≥0.0
1 
none 397,438 IMPUTE2 35; v21 none SNPTEST 1.00/1.0
1 
0.99/1.
01 
y 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
ERF illumina 
318K, 370K, 
Affymetrix 
250K 
BRLMM >98% >96% 10-6 >0.0
1 
ethnic outliers, 
gender 
mismatches, 
duplicates, 
excess IBS, 
incompatible 
with the 
pedigree, excess 
heterozygosity 
487,573 MACH1 36 v22 none ProbABEL 1.01 1.01 n 
Fenland AffymetrixS
NP 5.0 
BRLMM ≥0.95 ≥0.90 >10-6 ≥0.0
1 
none 362,59 IMPUTE2 
v0.4.2 
36; v22 none SNPTEST 0.99 0.99 y 
FHS Affymetrix 
500K and 
MIPS 50K 
combined 
BRLMM >=97
% 
>=0.97 >=10-6 >0.0
1 
Mishap p < 10-9, 
Mendelian err. > 
100 
378,163 MACH1 
v1.0.15 
36; v22 none LMEKIN 
package in R 
1.07 1.04 n 
FUSION 
controls 
Illumina 
HumanHap 
300 
Beadstudio
, clustering 
with 
FUSION 
97% ≥0.90 >10-6 >0.0
1 
>3 Mendel or 
duplicate errors 
304,581 MACH1 35; v21 r2hat 
<0.3 
Merlin 0.99/1.0
0 
1.00/1.
01 
n 
INCHIANTI Illumina 
550K 
Beadstudio >0.97 >0.99 >10-4 >0.0
1 
none 484,115 MACH1 
v1.0.15 
35; v21 r2hat 
<0.3, 
MAF < 
1% 
Merlin offline 0.99/1.0
1 
0.99/1.
01 
y 
INGI CARL Illumina 
370CNV 
BeadStudio >95% >90% >10-4 >=0.
01 
None 266389 MACH1 
v1.0.16 
36; v22 r2hat 
<0.3 
GenABEL/Prob
ABEL 
1.00 0.99 n 
INGI FVG Illumina 
370CNV 
BeadStudio >95% >90% >10-4 >=0.
01 
None 276271 MACH1 
v1.0.16 
36; v22 r2hat 
<0.3 
GenABEL/Prob
ABEL 
0.99 1.00 n 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
INGI Val 
Borbera 
Illumina 
HumanCNV
370-Quadv3  
Beadstudio >95% >90% >10-4 >=0.
01 
none 324,319 MACH1 36 v22 r2hat < 
0.3, 
average 
posterio
r 
probabil
ity < 
0.9, 
MAF >= 
0.01 
GenABEL/Prob
ABEL 
1/0.99 1.00/0.
99 
n 
KORA S3 Affymetrix 
500K 
BRLMM >0.93 
each 
chip 
>0.90 None ≥0.0
1 
none 490,032 MACH1 
v1.0.9 
35; v21 none PLINK 1.01/0.9
9 
1.01/1.
00 
y 
MICROS Illumina 
318K 
Beadstudio >98% >98% 10-6 >0.0
1 
ethnic outliers, 
gender 
mismatches, 
duplicates, 
excess IBS, 
incompatible 
with the 
pedigree, excess 
heterozygosity 
309,008 MACH1 36 v22 none ProbABEL 0.973 0.98 n 
MIGen 
controls 
 
 
 
 
Affymetrix 
6.0 (1M) 
BirdSuite1 ≥0.95 ≥0.95 ≥10-6 ≥0.0
1 
close relatives 750,407 MACH1 
v1.013 
36; v22 none SNPTEST 0.999/1.
036 
0.99/1.
02 
y 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
NESDA Perlegen 
600K 
Perlegen ≥.95 ≥0.95 None >0.0
1  genotype 
mismatches, 
errors, unknown 
SNP location; 
SAMPLES: ethnic 
outliers, XO and 
XXY samples, 
high genome-
wide homo- or 
heterozygosity, 
excess IBS 
435,291 IMPUTE2 
v0.3.2 
36; v22 none SNPTEST 
v1.1.4 
  1.02 y 
NFBC1966 Illumina 370 Beadstudio NA >0.95 >10-4 ≥0.0
1 
none 328,007 IMPUTE2 35; v21 none SNPTEST 1.02/1.0
3 
1.01/1.
03 
y 
NSPHS Illumina 
318K 
Beadstudio >98% >98% 10-6 >0.0
1 
ethnic outliers, 
gender 
mismatches, 
duplicates, 
excess IBS, 
excess 
heterozygosity 
  MACH1 36 v22 none ProbABEL 1.00 1.00 n 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
NTR Affymetrix 
600K/Perleg
en 
Perlegen 
Proprietary 
Calling 
Algorithm 
>0.90 >0.95 None ≥0.0
1 
Mendel errors > 
2; 
Duplicate errors 
> 2 
425,05 IMPUTE2 
0.5 
36; v24 proper 
info > 
0.30; 
r2hat > 
0.30; 
MAF > 
0.005 
SNPTEST 0.97 0.97 n 
ORCADES Illumina 
318K 
Beadstudio >98% >98% 10-6 >0.0
1 
ethnic outliers, 
gender 
mismatches, 
duplicates, 
excess IBS, 
incompatible 
with the 
pedigree, excess 
heterozygosity 
298,785 MACH1 36 v22 none ProbABEL 0.99 0.98 n 
PROCARDIS 
cntrols 
Illumina 1M Bead 
studio 
>0.95 >0.95 >10-3 Non
e 
none 882,598 IMPUTE2 
v0.3.2 
36; v22 none SNPTEST 0.99/1.0
3 
0.99/1.
02 
y 
RSI Illumina 
550K 
Beadstudio >=97.
5% 
>=0.98 >=10-6 >=0.
01 
none 530,683 MACH1 
v1.0.15 
36; v22 none ProbABEL 1.05 1.04 n 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
RSII Illumina 
550K 
Beadstudio >=97.
5% 
>=0.98 >10-6 >0.0
1 
none 495,478 MACH1 
v1.0.15 
36; v22 none ProbABEL 1.01 1.01 n 
SHIP Affymetrix 
SNP6.0 
BirdsuiteV2 >0.92 none None NA QC CR ≥0.86 869,224 IMPUTE2 
v0.5.0 
36; v22 none SNPTEST 1.01/1.0
1 
1.01/0.
99 
y 
SUVIMAX Illumina 
317K 
Beadstudio >0.94 none None NA none 302,607 IMPUTE2 
v0.3.2 
35; v21  none Custom C++ 1.01/0.9
9 
1.02/0.
99 
y 
TwinsUK Illumina 
317K 
Beadstudio NA >0.95 >10-6 in 
controls 
≥0.0
1 
SNPs mapping 
>1 loci 
303940  IMPUTE2 
V 0.4.2 
36; v22  none SNPTEST 1.00 1.01 y 
                                
Stage2                               
CROATIA-
Korcula 
Illumina 
CNV370_Du
o 
Beadstudio >97 >98 >10-6 >0.0
1 
none 316730 MACH1 
v1.0.15 
36; v22 none probABEL with 
mmscore 
function 
0.98* 0.99* n 
CROATIA-
Split 
Illumina 
CNV370_Qu
ad 
Beadstudio >97 >98 >10-6 >0.0
1 
none 331012 MACH1 
v1.0.15 
36; v22 none probABEL with 
mmscore 
function 
0.99* 0.99* n 
EGCUT+ Illumina 
370CNV 
Illumina 
BeadStudio 
≥95% ≥98% 10-6 ≥0.0
1 
Gryptic 
relatedness; 
Incomplete 
phenotype 
information 
326,339 IMPUTE2 
v0.5.0 
36; v22 none SNPTEST 0.99 0.99 n 
KORA F4 Affymetrix 
6.0 
Birdseed2 ≥ 0.93 none None none none 651596 IMPUTE2 
v0.4.2 
36; v22 none SNPTEST 1 1.00 n 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
LifeLines Illumina 
CytoSNP v 
2.0- 300K 
GenomeSt
udio 
>95 >99 >10-4 ≥0.0
1 
none 234833 IMPUTE2 
v0.3.2 
36; v22 None SNPTEST 0.99 1.00 n 
LOLIPOP_EW
_A 
Affymetrix 
500K 
BRLMM NA >0.90 >10-6 ≥0.0
1 
none 374773 MACH1 35; v21 MACH 
Rsq  ≥ 
0.3, maf 
≥0.01  
mach2qtl 0.99 0.99 n 
LOLIPOP_EW
_P 
Perlegen 
custom 
NA NA >0.90 >10-6 ≥0.0
1 
none 184469 MACH1 35; v21 MACH 
Rsq  ≥ 
0.3, maf 
≥0.01  
mach2qtl 0.99 0.99 n 
LOLIPOP_EW
610 
Illumina 
Human610 
Beadstudio NA >0.90 >10-6 ≥0.0
1 
none 544620 MACH1 36; v22 MACH 
Rsq  ≥ 
0.3, maf 
≥0.01  
mach2qtl 0.99 0.99 n 
LBC1921 Illumina 
Human  
610_Quadv
1 
Beadstudio >0.9
5 
>=0.98 >0.001 ≥0.0
1 
none 535709 MACH1 36; v22 None mach2qtl 0.99 0.99 n 
LBC1936 Illumina 
Human  
610_Quadv
1 
Beadstudio >=0.9
5 
>=0.98 >0.001 ≥0.0
1 
none 535709 MACH1 36; v22 None mach2qtl 1.01 1.01 n 
MESA Affymetrix 
SNP6.0 
Beadstudio >=95
% 
>=0.95 N/A >=0.
01 
heterozygosity<
=0.53 
872,242 IMPUTE2 
2.1.0 
36 none SNPTEST 1 1.00 n 
PROSPECT/P
HASE 
 Beadstudio >=97.
5% 
>=0.98 >10E-6 >0.0
1 
none NA NA NA NA SPSS NA NA n 
RSIII Illumina 
Human610 
Beadstudio >=97.
5% 
>=0.95 >=10-6 >=0.
01 
none 587,388 MACH1 
v1.0.15 
36; v22 none ProbABEL 1.00 1.01 n 
SardiNIA Affymetrix 
500 
BRLMM >0.95 >0.95 >10-6 >0.0
1 
none 356,359 MACH1 
v1.0.15 
35; v21 none Merlin offline 1.14 1.14 n 
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  Genotyping 
platform    
Calling 
algorithm    
Filtering of genotypes before imputation No. 
SNPs 
used for 
imputati
on 
Imputati
on 
software   
Imputati
on panel 
(NCBI 
version) 
Filtering 
of 
impute
d 
genotyp
es 
Genotype-
phenotype 
analysis 
software    
Genomic control 
lambda values 
Short 
cut for 
PP and 
MAP 
associati
on 
Cohort   Sampl
e 
Callrat
e 
SNP 
Callrate 
SNP 
HWE 
SNP 
MAF 
Other filter         SBP DBP  
YFS Illumina 
custom 
made 
BeadChip 
Human 670- 
Illuminus > 97 ≥ 95% >=10-6 ≥ 
0.01 
none 546674 MACH1 36;v22 none probABEL 0.99 1.01 n 
WGHS Illumina 
HumanHap 
300 DuoPlus 
Beadstudio 
3.3 
>=98
% 
>90% >=10-6 <0.0
1 
none 317,186 MACH1 
v1.0.15 
36; v22 none ProbABEL, R, 
bash scripting 
1.06 1.06 n 
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Supplementary Table 2  Association results for pulse pressure, mean arterial pressure, systolic blood pressure and diastolic blood pressure at all loci previously reported as showing 
association with SBP or DBP (or both), at all novel loci showing association with pulse pressure or mean arterial pressure (or both) and at loci selected for follow-up in stage 2. 
A) Pulse pressure association results from stage 1 (discovery), stage 2 (follow-up) and stages 1 and 2 combined for all previously reported SNPs at the 29 loci showing association with 
diastolic and/or systolic blood pressure and SNPs which reached nominal significance after stage 1 (P<1x10
-5
) for association with pulse pressure in those regions in this study.  For each 
region, the results for the top SNP in the pulse pressure analysis is shown along with the pulse pressure association results for the corresponding independently reported SNP in that 
region. * Study which first reported the SNP: Ehret et al
4
, Levy et al.
5
, Newton-Cheh et al.
6
 . # r
2
 of the top SNP in the region for pulse pressure and the independently reported SNP. 
rs1173756 is a synonymous coding SNP in C5orf23. 
 
Region 
SNP  
chr: NCBI 36 posn 
Study of 
origin* 
(r
2#
) 
Coded 
allele 
& freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
    
N 
effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
MTHFR 
rs17367504 
chr1: 11785365 Ehret et al 
G 
0.167 73689 -0.253 0.082 1.99E-03 46754 -0.198 0.104 5.66E-02 120442 -0.232 0.064 3.09E-04 
MOV10 
rs2932538 
chr1: 113018066 Ehret et al 
G 
0.742 67059 0.246 0.070 4.55E-04 38265 0.074 0.090 4.15E-01 105324 0.181 0.055 1.08E-03 
SLC4A7 
rs13082711 
chr3: 27512913 Ehret et al 
T 
0.798 69548 0.031 0.071 6.61E-01 39400 -0.181 0.092 4.90E-02 108948 -0.048 0.056 3.89E-01 
ULK4 
rs3774372 
chr3: 41852418 Ehret et al 
T 
0.775 73758 0.295 0.077 1.16E-04 44028 0.303 0.099 2.13E-03 117786 0.298 0.060 8.32E-07 
ULK4 
rs9815354 
chr3: 41887655 Levy et al 
G 
0.772 68807 0.277 0.079 4.27E-04 38418 0.291 0.104 4.92E-03 107224 0.282 0.063 6.63E-06 
MECOM 
rs419076 
chr3: 170583580 Ehret et al 
T 
0.436 73481 0.176 0.059 2.75E-03 41247 0.198 0.076 9.33E-03 114727 0.184 0.047 7.55E-05 
FGF5 
rs1458038 
chr4: 81383747 Ehret et al 
T 
0.3 68314 0.211 0.067 1.64E-03 39239 0.185 0.087 3.28E-02 107553 0.201 0.053 1.47E-04 
SLC39A8 
rs13107325 
chr4: 103407732 Ehret et al 
T 
0.117 63443 -0.338 0.124 6.52E-03 46534 -0.214 0.151 1.57E-01 109977 -0.288 0.096 2.69E-03 
GUCY1A3-
GUCY1B3 
rs13139571 
chr4: 156864963 Ehret et al 
C 
0.742 71136 0.088 0.070 2.09E-01 40739 0.139 0.089 1.20E-01 111875 0.107 0.055 5.14E-02 
NPR3-
C5orf23 
rs1173756 
chr5: 32825609 This study  
T 
0.525 73207 -0.324 0.059 4.10E-08 48371 -0.178 0.073 1.54E-02 121577 -0.267 0.046 6.85E-09 
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Region 
SNP  
chr: NCBI 36 posn 
Study of 
origin* 
(r
2#
) 
Coded 
allele 
& freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
    
N 
effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
NPR3-
C5orf23 
rs1173771 
chr5: 32850785 
Ehret et al 
(0.759) 
G 
0.525 73371 0.304 0.060 3.47E-07 43737 0.230 0.077 2.72E-03 117108 0.276 0.047 4.56E-09 
EBF1 
rs11953630 
chr5: 157777980 Ehret et al 
T 
0.342 73190 -0.214 0.061 4.32E-04 40852 -0.077 0.079 3.31E-01 114042 -0.163 0.048 7.16E-04 
HFE 
rs1799945 
chr6: 26199158 Ehret et al 
G 
0.182 70871 0.159 0.084 5.75E-02 40739 0.219 0.107 4.15E-02 111611 0.182 0.066 5.92E-03 
BAT2-BAT5 
rs805303 
chr6: 31724345 Ehret et al 
G 
0.653 73090 0.188 0.061 2.00E-03 45953 0.066 0.077 3.92E-01 119043 0.141 0.048 3.14E-03 
CACNB2(5') 
rs4373814 
chr10: 18459978 Ehret et al 
G 
0.633 71465 -0.143 0.060 1.68E-02 39833 0.034 0.078 6.62E-01 111298 -0.077 0.047 1.04E-01 
CACNB2(3') 
rs1813353 
chr10: 18747454 Ehret et al 
T 
0.649 72095 0.116 0.064 6.82E-02 40515 0.100 0.083 2.27E-01 112610 0.110 0.050 2.91E-02 
C10orf107 
rs4590817 
chr10: 63137559 Ehret et al 
G 
0.825 72693 0.236 0.081 3.42E-03 41049 0.352 0.104 7.35E-04 113742 0.280 0.064 1.18E-05 
PLCE-1 
rs9663362 
chr10: 95885167 This study  
G 
0.533 73597 -0.297 0.059 4.48E-07 43806 -0.228 0.075 2.48E-03 117404 -0.271 0.046 5.18E-09 
PLCE-1 
rs932764 
chr10: 95885930 
Ehret et al 
(0.845) 
G 
0.425 73110 0.281 0.059 2.09E-06 40896 0.211 0.078 6.71E-03 114007 0.255 0.047 6.08E-08 
CYP17A1-
NT5C2 
rs1004467 
chr10: 104584497 
Levy et al 
(1.0) 
G 
0.067 72728 -0.597 0.098 1.07E-09 41226 -0.280 0.127 2.71E-02 113954 -0.479 0.078 6.47E-10 
CYP17A1-
NT5C2 
rs3824755 
chr10: 104585839 This study  
G 
0.933 73054 0.597 0.098 9.96E-10 41366 0.274 0.127 3.07E-02 114420 0.477 0.077 7.33E-10 
CYP17A1-
NT5C2 
rs11191548 
chr10: 104836168 
Ehret et al 
(0.485) 
T 
0.942 71891 0.573 0.104 3.59E-08 43947 0.459 0.130 4.18E-04 115837 0.529 0.081 7.68E-11 
ADM 
rs17296765 
chr11: 10288865 This study  
T 
0.142 72230 0.472 0.090 1.50E-07 40152 0.157 0.120 1.92E-01 112382 0.359 0.072 6.05E-07 
ADM 
rs7129220 
chr11: 10307114 
Ehret et al 
(0.932) 
G 
0.867 69401 -0.470 0.094 6.12E-07 41420 -0.223 0.124 7.31E-02 110821 -0.380 0.075 4.25E-07 
PLEKHA7 
rs381815 
chr11: 16858844 
This 
study/ 
Ehret et al 
T 
0.297 72901 0.308 0.066 3.47E-06 41243 0.113 0.087 1.91E-01 114144 0.236 0.053 7.48E-06 
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Region 
SNP  
chr: NCBI 36 posn 
Study of 
origin* 
(r
2#
) 
Coded 
allele 
& freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
    
N 
effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
FLJ32810-
TMEM133 
rs633185 
chr11: 100098748 Ehret et al 
G 
0.317 72563 -0.258 0.065 7.94E-05 40956 -0.126 0.085 1.37E-01 113519 -0.209 0.052 5.49E-05 
ATP2B1 
rs2681472 
chr12: 88533090 
Levy et al 
(1.0) 
G 
0.11 73533 -0.383 0.080 1.75E-06 45786 -0.342 0.101 7.30E-04 119320 -0.367 0.063 5.07E-09 
ATP2B1 
rs2681492 
chr12: 88537220 
Levy et al 
(0.92) 
T 
0.883 70236 0.381 0.078 1.18E-06 44422 0.307 0.099 1.96E-03 114658 0.353 0.062 9.91E-09 
ATP2B1 
rs17249754 
chr12: 88584717 
This 
study/ 
Ehret et al 
G 
0.892 72022 0.393 0.081 1.09E-06 43658 0.391 0.102 1.25E-04 115680 0.392 0.063 5.54E-10 
ATXN2 
rs3184504 
chr12: 110368991 Ehret et al 
T 
0.408 69741 0.097 0.060 1.09E-01 45074 0.199 0.075 7.94E-03 114815 0.137 0.047 3.57E-03 
ATXN2 
rs2384550 
chr12: 113837114 Levy et al 
G 
0.658 73810 0.130 0.062 3.46E-02 48126 0.075 0.078 3.37E-01 121936 0.109 0.048 2.43E-02 
TBX5-TBX3 
rs10850411 
chr12: 113872179 Ehret et al 
T 
0.717 69558 0.088 0.065 1.77E-01 38948 0.170 0.086 4.79E-02 108506 0.118 0.052 2.30E-02 
CSK 
rs1378942 
chr15: 72864420 Ehret et al 
C 
0.333 73412 0.108 0.061 7.89E-02 48324 0.210 0.077 6.63E-03 121736 0.147 0.048 2.18E-03 
FES 
rs2521501 
chr15: 89238392 Ehret et al 
T 
0.373 43863 0.295 0.083 3.72E-04 28743 0.109 0.096 2.55E-01 72606 0.216 0.063 5.90E-04 
GOSR2 
rs17608766 
chr17: 42368270 
This 
study/ 
Ehret et al 
T 
0.908 62353 -0.578 0.088 5.18E-11 41303 -0.467 0.109 1.90E-05 103656 -0.534 0.069 6.39E-15 
ZNF652 
rs12940887 
chr17: 44757806 Ehret et al 
T 
0.417 72190 0.055 0.061 3.69E-01 43164 -0.024 0.078 7.58E-01 115355 0.025 0.048 6.06E-01 
JAG1 
rs1327235 
chr20:10917030 Ehret et al 
G 
0.575 72861 0.105 0.059 7.56E-02 43734 0.116 0.075 1.23E-01 116595 0.109 0.047 1.88E-02 
GNAS-
EDN3 
rs6015450 
chr20: 57184512 Ehret et al 
G 
0.067 71156 0.358 0.092 9.47E-05 35995 0.343 0.122 5.12E-03 107151 0.352 0.073 1.56E-06 
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B) Mean arterial pressure association results from stage 1 (discovery), stage 2 (follow-up) and stages 1 and 2 combined for all previously reported SNPs at the 29 loci showing association 
with diastolic and/or systolic blood pressure and SNPs which reached nominal significance after stage 1 (P<1x10
-5
) for association with mean arterial pressure in those regions in this 
study.  For each region, the results for the top SNP in the mean arterial pressure analysis is shown along with the mean arterial pressure association results for the corresponding 
independently reported SNP in that region. * Study which first reported the SNP: Ehret et al
4
, Levy et al
5
, Newton-Cheh et al 
6
.  # r
2
 of the top SNP in the region for mean arterial pressure 
and the independently reported SNP. 
Region SNP ID 
Study of 
origin* (r
2#
) 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
    
N 
effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
MTHFR-
NPPB 
rs17367504 
chr1:11785365 
This study/ 
Ehret et al / 
Newton- Cheh 
et al  
G 
0.167 73689 
-
0.464 0.082 1.86E-08 48460 -0.652 0.106 8.03E-10 122149 -0.534 0.065 2.18E-16 
MOV10 
rs2932538 
chr1:113018066 Ehret et al 
G 
0.742 67059 0.286 0.070 4.55E-05 38236 0.189 0.096 4.79E-02 105295 0.252 0.057 8.25E-06 
SLC4A7 
rs13082711 
chr3: 27512913 
This study/ 
Ehret et al 
T 
0.798 69548 
-
0.350 0.071 8.08E-07 39379 -0.309 0.097 1.47E-03 108927 -0.336 0.057 4.62E-09 
ULK4 
rs3774372 
chr3: 41852418 Ehret et al 
T 
0.775 73758 
-
0.211 0.076 5.46E-03 44030 0.008 0.104 9.40E-01 117788 -0.135 0.061 2.77E-02 
ULK4 
rs9815354 
chr3: 41887655 Levy et al 
G 
0.772 68807 
-
0.224 0.078 4.09E-03 38405 -0.004 0.110 9.70E-01 107212 -0.150 0.064 1.81E-02 
MECOM 
rs419076 
chr3:170583580 
Ehret et al 
(0.872) 
T 
0.436 73481 0.348 0.059 3.00E-09 41240 0.326 0.081 5.94E-05 114721 0.340 0.048 8.11E-13 
MECOM 
rs1343040 
chr3:170668987 This study  
G 
0.6 67087 
-
0.370 0.062 2.22E-09 35208 -0.287 0.087 1.04E-03 102295 -0.342 0.050 1.22E-11 
FGF5 
rs13149993 
chr4: 81377569 This study  
G 
0.633 71616 
-
0.415 0.063 3.29E-11 42618 -0.191 0.086 2.60E-02 114234 -0.337 0.051 2.55E-11 
FGF5 
rs1458038 
chr4: 81383747 
Ehret et al 
(0.503) 
T 
0.3 68314 0.430 0.066 5.34E-11 40797 0.352 0.090 9.36E-05 109111 0.403 0.053 2.88E-14 
FGF5 
rs16998073 
chr4: 81403365 
Newton-Cheh 
et al (0.503) 
T 
0.192 55070 0.486 0.077 3.33E-10 32592 0.389 0.106 2.42E-04 87662 0.453 0.063 4.53E-13 
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Region SNP ID 
Study of 
origin* (r
2#
) 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
    
N 
effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
SLC39A8 
rs13107325 
chr4:103407732 
This study/ 
Ehret et al 
T 
0.117 63443 
-
0.670 0.127 1.34E-07 46594 -0.577 0.156 2.13E-04 110037 -0.633 0.098 1.30E-10 
GUCY1A3-
GUCY1B3 
rs13139571 
chr4:156864963 Ehret et al 
C 
0.742 71136 0.298 0.070 1.93E-05 40732 0.272 0.095 4.05E-03 111869 0.289 0.056 2.69E-07 
NPR3-
C5orf23 
rs1173771 
chr5:32850785 
This study/ 
Ehret et al 
G 
0.525 73371 0.289 0.059 1.07E-06 43737 0.271 0.081 8.58E-04 117109 0.283 0.048 3.51E-09 
EBF1 
rs9313772 
chr5:157737035 This study 
T 
0.317 70895 
-
0.279 0.062 6.24E-06 43103 -0.436 0.083 1.63E-07 113998 -0.335 0.050 1.48E-11 
EBF1 
rs11953630 
chr5:157777980 
Ehret et al 
(0.012) 
T 
0.342 73190 
-
0.268 0.061 1.06E-05 40829 -0.457 0.084 5.72E-08 114019 -0.332 0.049 1.51E-11 
HFE 
rs1799945 
chr6: 26199158 
Ehret et al 
(1.0) 
G 
0.182 70871 0.440 0.085 2.06E-07 40730 0.515 0.114 6.07E-06 111601 0.467 0.068 6.55E-12 
HFE 
rs198846 
chr6: 26215442 This study  
G 
0.858 71385 
-
0.445 0.085 1.53E-07 40292 -0.539 0.115 2.55E-06 111677 -0.478 0.068 2.26E-12 
BAT2-BAT5 
rs805303 
chr6:31724345 Ehret et al 
G 
0.653 73090 0.186 0.061 2.14E-03 45959 0.098 0.080 2.24E-01 119049 0.154 0.048 1.45E-03 
CACNB2(5') 
rs4373814 
chr10:18459978 Ehret et al 
G 
0.633 71465 
-
0.244 0.060 4.55E-05 39854 -0.044 0.083 5.99E-01 111318 -0.175 0.048 3.01E-04 
CACNB2(3') 
rs1813353 
chr10:18747454 
Ehret et al 
(0.826) 
T 
0.649 72095 0.407 0.064 1.71E-10 40513 0.391 0.088 8.40E-06 112608 0.402 0.052 7.01E-15 
CACNB2(3') 
rs11014166 
chr10:18748804 
Levy et al 
(0.826) 
T 
0.367 73317 
-
0.385 0.062 4.84E-10 41146 -0.363 0.085 1.99E-05 114464 -0.377 0.050 4.59E-14 
CACNB2(3') 
rs12258967 
chr10:18767965 This study  
G 
0.364 67411 
-
0.418 0.065 1.37E-10 38762 -0.456 0.089 2.67E-07 106173 -0.431 0.052 2.05E-16 
C10orf107 
rs4590817 
chr10:63137559 
This study/ 
Ehret et al 
G 
0.825 72693 0.544 0.082 2.98E-11 41049 0.634 0.111 1.03E-08 113742 0.576 0.066 2.14E-18 
C10orf107 
rs1530440 
chr10:63194597 
Newton-Cheh 
et al (0.592) 
T 
0.175 70613 
-
0.442 0.075 4.77E-09 42677 -0.638 0.103 5.15E-10 113290 -0.511 0.061 4.50E-17 
PLCE-1 
rs932764 
chr10:95885930 
Ehret et al 
(0.845) 
G 
0.425 73110 0.184 0.059 1.86E-03 40896 0.243 0.083 3.27E-03 114006 0.204 0.048 2.22E-05 
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Region SNP ID 
Study of 
origin* (r
2#
) 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
    
N 
effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
CYP17A1-
NT5C2 
rs1004467 
chr10:104584497 
Levy et al 
(0.867) 
G 
0.067 72728 
-
0.563 0.096 5.01E-09 41208 -0.658 0.135 1.01E-06 113937 -0.595 0.078 2.94E-14 
CYP17A1-
NT5C2 
rs11191548 
chr10:104836168 
Newton-Cheh 
et al / Ehret et 
al (0.485) 
T 
0.942 71891 0.589 0.102 8.68E-09 43943 0.759 0.137 2.91E-08 115834 0.650 0.082 2.19E-15 
CYP17A1-
NT5C2 
rs11191593 
chr10:104929205 This study  
T 
0.942 71214 0.612 0.102 1.86E-09 41171 0.749 0.140 9.01E-08 112385 0.660 0.082 1.20E-15 
ADM 
rs7129220 
chr11:10307114 
Ehret et al 
(0.932) 
G 
0.867 69401 
-
0.330 0.093 4.05E-04 41440 -0.314 0.132 1.77E-02 110841 -0.325 0.076 2.07E-05 
PLEKHA7 
rs381815 
chr11:16858844 Ehret et al 
T 
0.297 72901 0.276 0.066 2.74E-05 41221 0.340 0.092 2.25E-04 114122 0.298 0.054 2.75E-08 
FLJ32810-
TMEM33 
rs633185 
chr11: 100098748 
Ehret et al 
(1.0) 
G 
0.317 72563 
-
0.340 0.065 1.57E-07 40963 -0.296 0.090 1.01E-03 113526 -0.325 0.053 6.58E-10 
FLJ32810-
TMEM33 
rs604723 
chr11:100115756 This study  
T 
0.317 73368 
-
0.343 0.065 1.19E-07 45581 -0.252 0.087 3.83E-03 118949 -0.310 0.052 2.30E-09 
ATP2B1 
rs2681472 
chr12:88533090 Levy et al (1.0) 
G 
0.11 73533 
-
0.553 0.081 1.00E-11 45787 -0.516 0.106 1.02E-06 119321 -0.539 0.064 5.51E-17 
ATP2B1 
rs2681492 
chr12:88537220 
Levy et al 
(0.92) 
T 
0.883 70236 0.530 0.080 3.36E-11 44426 0.524 0.106 8.37E-07 114662 0.528 0.064 1.46E-16 
ATP2B1 
rs17249754 
chr12:88584717 
This study/ 
Ehret et al 
G 
0.892 72022 0.563 0.082 6.01E-12 43664 0.545 0.107 3.74E-07 115686 0.557 0.065 1.21E-17 
ATXN2 
rs3184504 
chr12:110368991 
Levy et al/ 
Ehret et al 
(1.0) 
T 
0.408 69741 0.394 0.060 4.25E-11 45072 0.446 0.078 1.33E-08 114813 0.413 0.048 3.64E-18 
ATXN2 
rs653178 
chr12:110492139 
This study / 
Newton-Cheh 
et al 
T 
0.592 70336 
-
0.401 0.060 1.74E-11 48308 -0.475 0.076 4.97E-10 118644 -0.429 0.047 6.91E-20 
TBX5-TBX3 
rs2384550 
chr12:113837114 
This 
study/Levy et 
al 
G 
0.658 73810 0.277 0.062 7.72E-06 48126 0.142 0.081 7.99E-02 121936 0.227 0.049 3.89E-06 
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Region SNP ID 
Study of 
origin* (r
2#
) 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
    
N 
effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
TBX5-TBX3 
rs10850411 
chr12:113872179 Ehret et al 
T 
0.717 69558 0.247 0.066 1.66E-04 38921 0.240 0.091 8.71E-03 108479 0.245 0.053 4.44E-06 
CSK 
rs1378942 
chr15:72864420 
This study/ 
Ehret et al 
/Newton-
Cheh et al 
(2009) 
C 
0.333 73412 0.365 0.061 1.90E-09 48323 0.424 0.080 1.39E-07 121735 0.386 0.048 1.63E-15 
CSK 
rs6495122 
chr15:72912698 
Levy et al 
(0.585) 
C 
0.583 72332 
-
0.310 0.059 1.69E-07 45465 -0.337 0.079 1.83E-05 117797 -0.320 0.047 1.42E-11 
FES 
rs2521501 
chr15:89238392 Ehret et al 
T 
0.373 43863 0.337 0.078 1.71E-05 30021 0.356 0.101 4.47E-04 73884 0.344 0.062 2.88E-08 
GOSR2 
rs17608766 
chr17:42368270 Ehret et al 
T 
0.908 62353 
-
0.359 0.088 4.91E-05 41327 -0.372 0.114 1.12E-03 103681 -0.364 0.070 1.94E-07 
ZNF652 
rs12940887 
chr17:44757806 Ehret et al 
T 
0.417 72190 0.290 0.061 1.77E-06 43157 0.182 0.082 2.68E-02 115347 0.252 0.049 2.47E-07 
ZNF652 
rs16948048 
chr17:44795465 
This 
study/Newton
-Cheh et al 
G 
0.425 73219 0.304 0.060 4.49E-07 43510 0.147 0.082 7.12E-02 116730 0.249 0.049 2.88E-07 
JAG1 
rs1327235 
chr20:10917030 Ehret et al 
G 
0.575 72861 0.234 0.059 6.85E-05 43732 0.305 0.080 1.30E-04 116594 0.259 0.047 4.35E-08 
GNAS-EDN3 
rs6026748 
chr20:57179210 This study  
G 
0.933 71668 
-
0.416 0.089 2.81E-06 40270 -0.674 0.127 1.00E-07 111938 -0.501 0.073 5.45E-12 
GNAS-EDN3 
rs6015450 
chr20:57184512 Ehret et al 
G 
0.067 71156 0.413 0.089 3.62E-06 35998 0.756 0.131 8.54E-09 107154 0.521 0.074 1.58E-12 
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C) Pulse pressure and mean arterial pressure association results from stage 1 (discovery), stage 2 (follow-up) and stages 1 and 2 combined for all 46 SNPs that showed nominally 
significant association (P<1x10
-5
) after stage 1.  Both rs1595373 and rs1156725 in SOX6 were included because rs1595373 (P=4.23x10
-6
) had an N effective of 75% which was above the 
threshold (70%) at which we would choose a proxy but the second strongest signal in the region (rs1156725) had a very similar P value (P=4.24x10
-6
) and an N effective of 99.6%. These 
SNPs were correlated (r= 0.64) and it was deemed appropriate to take both SNPs for forward to stage 2. 
SNP ID gene 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
Pulse Pressure   N effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
rs11222084 
chr11:129778440 near ADAMTS-8 
T 
0.375 67704 0.415 0.064 8.45E-11 40391 0.211 0.081 9.17E-03 108095 0.337 0.050 1.90E-11 
rs17477177 
chr7:106199094 near PIK3CG 
T 
0.717 72997 -0.460 0.071 1.19E-10 39999 -0.344 0.094 2.72E-04 112996 -0.418 0.057 2.27E-13 
rs8069437 
chr17:42261948 near WNT3 
T 
0.167 62041 0.479 0.076 3.85E-10 38084 0.276 0.097 4.46E-03 100125 0.401 0.060 2.45E-11 
rs1427547 
chr2:19603457 near OSR1 
T 
0.467 73703 0.288 0.059 1.13E-06 45889 0.007 0.075 9.25E-01 119591 0.180 0.046 1.04E-04 
rs7788972 
chr7:19000805 HDAC9 (intron) 
T 
0.76 69597 -0.360 0.075 1.57E-06 39481 -0.040 0.099 6.84E-01 109078 -0.243 0.060 4.70E-05 
rs917275 
chr7:28625047 CREB5 (intron) 
G 
0.405 73606 0.287 0.060 1.84E-06 47283 0.030 0.075 6.86E-01 120889 0.187 0.047 6.92E-05 
rs12052878 
chr2:237892333 near COL6A3 
G 
0.707 62708 0.323 0.069 2.51E-06 35420 0.083 0.086 3.33E-01 98128 0.229 0.054 1.84E-05 
rs429150 
chr6:32183541 TNXB (intron) 
T 
0.65 66730 -0.289 0.062 2.65E-06 34553 -0.196 0.081 1.52E-02 101283 -0.255 0.049 1.93E-07 
rs480211 
chr11:63496015 near COX8A 
T 
0.517 69801 -0.280 0.060 3.52E-06 47928 -0.120 0.075 1.07E-01 117729 -0.217 0.047 3.87E-06 
rs10762174 
chr10:69006097 CTNNA3 (intron) 
G 
0.892 72322 -0.329 0.071 3.98E-06 41064 -0.141 0.093 1.30E-01 113386 -0.259 0.057 4.55E-06 
rs8009633 
chr14:52456586 FERMT2 (intron) 
G 
0.742 63871 -0.333 0.072 4.27E-06 38595 -0.117 0.090 1.96E-01 102466 -0.249 0.057 1.10E-05 
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SNP ID gene 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
  N effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
rs2165094 
chr2:164881280 near GRB14 
G 
0.092 56187 -0.452 0.098 4.34E-06 30047 -0.206 0.139 1.39E-01 86235 -0.370 0.080 4.12E-06 
rs13002573 
chr2:164623454 near FIGN 
G 
0.203 73043 -0.320 0.070 5.43E-06 43955 -0.296 0.089 8.58E-04 116998 -0.310 0.055 1.76E-08 
rs999958 
chr4:169935448 PALLD (intron) 
C 
0.475 73539 0.267 0.059 5.49E-06 45892 0.056 0.074 4.51E-01 119431 0.186 0.046 5.47E-05 
rs2071518 
chr8:120504993 NOV (3' UTR) 
T 
0.167 73252 0.304 0.067 5.72E-06 45804 0.323 0.086 1.60E-04 119056 0.312 0.053 3.66E-09 
rs4870322 
chr6:155315056 near TIAM2 
G 
0.467 53999 0.318 0.070 5.87E-06 46157 0.046 0.076 5.45E-01 100157 0.193 0.052 1.83E-04 
rs10410907 
chr19:45724949 SPTBN4 (intron) 
T 
0.093 56263 -0.502 0.111 6.50E-06 36522 0.089 0.139 5.24E-01 92785 -0.271 0.087 1.81E-03 
rs9296832 
chr6:56208868 
COL21A1 
(intron) 
G 
0.558 63322 -0.281 0.062 6.85E-06 33362 -0.195 0.083 1.87E-02 96685 -0.250 0.050 5.46E-07 
rs137602 
chr22:38023354 near RPL3 
G 
0.425 70724 0.276 0.061 6.92E-06 44829 -0.004 0.077 9.55E-01 115553 0.167 0.048 5.01E-04 
rs4778850 
chr15:78821473 
FAM108C1 
(intron) 
G 
0.231 72975 -0.328 0.073 7.03E-06 41097 -0.014 0.095 8.83E-01 114073 -0.211 0.058 2.67E-04 
rs2865531 
chr16:73947817 CFDP1 (intron) 
T 
0.467 73439 -0.265 0.059 7.94E-06 41244 0.076 0.078 3.30E-01 114683 -0.139 0.047 3.15E-03 
rs4147046 
chr4:18309880 near LCORL 
T 
0.596 69266 -0.277 0.062 9.20E-06 39886 -0.023 0.080 7.73E-01 109152 -0.182 0.049 2.33E-04 
rs871606 
chr4:54494002 near CHIC2  
T 
0.85 71444 0.428 0.096 9.28E-06 44082 0.431 0.121 3.75E-04 115525 0.429 0.075 1.32E-08 
rs13250217 
chr8:124367626 near ZHX1 
G 
0.317 56943 -0.323 0.073 9.50E-06 31134 0.042 0.094 6.54E-01 88077 -0.187 0.058 1.23E-03 
Mean Arterial Pressure 
rs754868 
chr2:43039036 near HAAO 
G 
0.533 72880 -0.313 0.059 1.16E-07 45717 -0.113 0.079 1.49E-01 118597 -0.241 0.047 3.35E-07 
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SNP ID gene 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
   N effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
rs9290370 
chr3:170807707 near MECOM 
T 
0.267 70889 -0.337 0.067 4.72E-07 43539 -0.155 0.089 8.35E-02 114428 -0.272 0.054 3.97E-07 
rs7213273 
chr17:40511440 PLCD3 
G 
0.4 71459 0.311 0.063 7.06E-07 43397 0.137 0.084 1.02E-01 114856 0.249 0.050 7.33E-07 
rs1687295 
chr3:14864760 FGD5 (intron) 
T 
0.392 68990 0.329 0.067 9.93E-07 39081 0.226 0.091 1.32E-02 108071 0.293 0.054 6.37E-08 
rs2782980 
chr10:115771517 near ADRB1 
T 
0.198 61284 -0.345 0.071 1.14E-06 37788 -0.326 0.094 5.55E-04 99072 -0.338 0.057 2.46E-09 
rs17432448 
chr7:18514944 HDAC9 (intron) 
G 
0.342 63902 0.308 0.064 1.26E-06 35734 -0.026 0.089 7.71E-01 99636 0.195 0.052 1.60E-04 
rs16893776 
chr8:96042780 C8orf38 (intron) 
T 
0.533 73714 -0.282 0.058 1.41E-06 43891 0.037 0.079 6.38E-01 117605 -0.170 0.047 3.13E-04 
rs1446468 
chr2:164671732 near FIGN 
T 
0.534 69264 -0.291 0.061 1.68E-06 39650 -0.418 0.082 3.80E-07 108914 -0.336 0.049 6.46E-12 
rs10841376 
chr12:19871148 near AEBP2 
G 
0.2 70805 -0.340 0.072 2.18E-06 42157 -0.161 0.095 9.12E-02 112961 -0.275 0.057 1.58E-06 
rs2969070 
chr7:2479071 near CHST12 
G 
0.367 70046 0.299 0.063 2.23E-06 46598 0.168 0.081 3.88E-02 116644 0.250 0.050 5.61E-07 
rs4403412 
chr8:10190691 MSRA (intron) 
T 
0.263 72942 0.297 0.063 2.31E-06 40811 0.227 0.087 8.92E-03 113753 0.273 0.051 8.33E-08 
rs9276348 
chr6:32814187 near HLA-DQA2 
G 
0.206 68860 -0.340 0.073 2.92E-06 39026 -0.081 0.098 4.08E-01 107886 -0.248 0.058 2.16E-05 
rs2180768 
chr1:52490409 ZFYVE9 (intron) 
G 
0.9 62194 -0.472 0.101 2.94E-06 41084 0.162 0.125 1.93E-01 103278 -0.221 0.078 4.94E-03 
rs7246865 
chr19:17080105 MYO9B (intron) 
G 
0.767 66984 -0.326 0.070 2.97E-06 41002 -0.224 0.093 1.66E-02 107986 -0.289 0.056 2.25E-07 
rs1957563 
chr5157407168 near CLINT1 
T 
0.208 73786 0.314 0.067 3.28E-06 44019 0.202 0.090 2.45E-02 117805 0.273 0.054 3.96E-07 
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SNP ID gene 
Coded 
allele & 
freq Stage 1 Stage 2 Combined Stage 1 + Stage 2 
   N effective Beta SE P 
N 
effective Beta SE P 
N 
effective Beta SE P 
rs2838351 
chr21:43935212 RRP1B  (intron) 
G 
0.508 64473 0.294 0.063 3.47E-06 35756 0.161 0.088 6.60E-02 100229 0.248 0.051 1.30E-06 
rs319690 
chr3:47902488 MAP4 (intron) 
T 
0.51 59137 0.306 0.066 3.88E-06 34359 0.280 0.090 1.89E-03 93496 0.297 0.053 2.69E-08 
rs1595373 
chr11:16223316 SOX6 (intron) 
G 
0.098 55351 0.450 0.098 4.23E-06 36981 0.283 0.122 2.00E-02 92332 0.385 0.076 4.59E-07 
rs1156725 
chr11:16264276 SOX6 (intron) 
T 
0.817 73779 -0.342 0.074 4.24E-06 45957 -0.263 0.099 7.64E-03 119736 -0.314 0.059 1.30E-07 
rs919734 
chr5:148329466 near SH3TC2 
G 
0.775 70685 0.326 0.071 4.26E-06 38952 0.189 0.100 5.86E-02 109637 0.280 0.058 1.26E-06 
rs7110667 
chr11:33984657 near CAPRIN1 
T 
0.258 62249 0.336 0.074 4.77E-06 32108 0.220 0.106 3.83E-02 94357 0.299 0.060 7.82E-07 
rs10175915 
chr2:72341668 EXOC6B (intron) 
T 
0.817 73114 0.366 0.082 7.13E-06 43748 0.091 0.108 4.01E-01 116861 0.267 0.065 4.28E-05 
rs1161267 
chr2:72975689 near SPR 
G 
0.883 68021 0.477 0.107 7.78E-06 38735 0.021 0.140 8.82E-01 106756 0.309 0.085 2.69E-04 
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D)  Systolic blood pressure association results for the 8 SNPs at the seven loci found to have novel association with pulse pressure and/or mean arterial pressure in Europeans in the 
present study and all 29 loci previously associated with diastolic and/or systolic blood pressure. Stage 1 and stage 2 samples are those described in Supplementary Table 1 and which were 
used for the primary pulse pressure and mean arterial pressure analyses. Loci which reach genome-wide significance (P<5x10
-8
) after the combined stage 1 and stage 2 analysis are 
highlighted in bold.   
 
Region 
SNP  
Chr: NCBI 36 
posn 
Coded 
allele & 
freq SBP Stage 1 SBP Stage 2 SBP Combined Stage 1 + Stage 2 
    N eff Beta SE P N eff Beta SE P N eff Beta SE P 
Novel loci associated with Pulse Pressure in this study 
near FIGN 
rs13002573 
chr2:164623454 
G 
0.203 73076 -0.411 0.104 7.59E-05 43956 -0.424 0.131 1.25E-03 117033 -0.416 0.081 3.25E-07 
near CHIC2  
rs871606 
chr4:54494002 
T 
0.85 68870 0.423 0.143 3.11E-03 44042 0.372 0.178 3.69E-02 112912 0.403 0.112 3.04E-04 
near 
PIK3CG 
rs17477177 
chr7:106199094 
T 
0.717 72959 -0.513 0.106 1.17E-06 39984 -0.621 0.140 9.09E-06 112943 -0.552 0.084 5.67E-11 
NOV (3' 
UTR) 
rs2071518 
chr8:120504993 
T 
0.167 73118 0.156 0.100 1.18E-01 45807 0.220 0.126 8.03E-02 118925 0.181 0.078 2.08E-02 
near 
ADAMTS-8 
rs11222084 
chr11:129778440 
T 
0.375 67856 0.325 0.095 5.95E-04 40395 0.164 0.120 1.73E-01 108251 0.263 0.074 4.00E-04 
Novel loci associated with Mean Arterial Pressure in this study 
near FIGN 
rs1446468 
chr2:164671732 
T 
0.534 69382 -0.458 0.090 3.47E-07 39650 -0.565 0.115 8.58E-07 109032 -0.499 0.071 1.82E-12 
MAP4 
(intron) 
rs319690 
chr3:47902488 
T 
0.51 59312 0.457 0.098 3.45E-06 34366 0.368 0.126 3.36E-03 93678 0.423 0.077 4.74E-08 
near 
ADRB1 
rs2782980 
chr10:115771517 
T 
0.198 61020 -0.389 0.105 2.14E-04 37792 -0.433 0.132 1.00E-03 98811 -0.406 0.082 7.66E-07 
Loci previously associated with SBP and/or DBP (Ehret et al 2011) 
MTHFR-
NPPB 
rs17367504 
chr1:11785365 
G 
0.167 71215 -0.837 0.121 5.26E-12 48460 -0.817 0.150 4.65E-08 119675 -0.829 0.094 1.38E-18 
MOV10 
rs2932538 
chr1:113018066 
G 
0.825 67279 0.533 0.104 3.22E-07 38127 0.241 0.134 7.08E-02 105406 0.422 0.082 2.72E-07 
SLC4A7 
rs13082711 
chr3:27512913 
T 
0.798 69820 -0.338 0.106 1.40E-03 39384 -0.449 0.136 9.36E-04 109204 -0.380 0.083 5.28E-06 
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Region 
SNP  
Chr: NCBI 36 
posn 
Coded 
allele & 
freq SBP Stage 1 SBP Stage 2 SBP Combined Stage 1 + Stage 2 
    N eff Beta SE P N eff Beta SE P N eff Beta SE P 
ULK4 
rs3774372 
chr3:41852418 
T 
0.717 73830 -0.018 0.113 8.76E-01 44031 0.219 0.146 1.33E-01 117861 0.071 0.089 4.26E-01 
MECOM 
rs419076 
chr3:170583580 
T 
0.436 73554 0.523 0.087 1.89E-09 41244 0.461 0.113 4.43E-05 114799 0.500 0.069 4.09E-13 
FGF5 
rs1458038 
chr4:81383747 
T 
0.3 65888 0.643 0.099 8.03E-11 40780 0.475 0.126 1.54E-04 106667 0.579 0.078 9.42E-14 
SLC39A8 
rs13107325 
chr4:103407732 
T 
0.117 61128 -1.033 0.185 2.17E-08 46585 -0.709 0.222 1.38E-03 107713 -0.900 0.142 2.16E-10 
GUCY1A3-
GUCY1B3 
rs13139571 
chr4:156864963 
C 
0.772 71406 0.486 0.103 2.52E-06 40813 0.369 0.132 5.12E-03 112220 0.442 0.081 5.60E-08 
NPR3-
C5orf23 
rs1173771 
chr5:32850785 
G 
0.525 73338 0.578 0.089 6.62E-11 43736 0.416 0.114 2.53E-04 117074 0.517 0.070 1.39E-13 
EBF1 
rs11953630 
chr5:157777980 
T 
0.342 73093 -0.461 0.090 3.34E-07 40844 -0.514 0.117 1.19E-05 113936 -0.480 0.072 1.86E-11 
HFE 
rs1799945 
chr6:26199158 
G 
0.182 71053 0.549 0.125 1.18E-05 40734 0.656 0.159 3.75E-05 111787 0.590 0.098 2.04E-09 
BAT2-BAT5 
rs805303 
chr6:31724345 
G 
0.575 70902 0.415 0.090 3.84E-06 45924 0.151 0.113 1.80E-01 116826 0.313 0.070 8.52E-06 
CACNB2(5') 
rs4373814 
chr10:18459978 
G 
0.408 71383 -0.421 0.089 2.14E-06 40029 -0.033 0.115 7.74E-01 111412 -0.276 0.070 8.60E-05 
CACNB2(3') 
rs1813353 
chr10:18747454 
T 
0.649 71774 0.500 0.094 1.15E-07 40514 0.493 0.122 5.66E-05 112288 0.497 0.075 2.77E-11 
C10orf107 
rs4590817 
chr10:63137559 
G 
0.825 72405 0.729 0.120 1.22E-09 41050 0.886 0.155 9.98E-09 113455 0.788 0.095 9.24E-17 
PLCE-1 
rs932764 
chr10:95885930 
G 
0.425 72821 0.442 0.088 4.99E-07 40896 0.393 0.115 6.30E-04 113717 0.424 0.070 1.28E-09 
CYP17A1-
NT5C3 
rs11191548 
chr10:104836168 
T 
0.942 71609 1.069 0.155 5.44E-12 43945 1.049 0.192 4.76E-08 115553 1.061 0.121 1.44E-18 
ADM 
rs7129220 
chr11:10307114 
G 
0.867 69577 -0.806 0.140 7.86E-09 41429 -0.452 0.184 1.43E-02 111006 -0.676 0.111 1.21E-09 
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Region 
SNP  
Chr: NCBI 36 
posn 
Coded 
allele & 
freq SBP Stage 1 SBP Stage 2 SBP Combined Stage 1 + Stage 2 
    N eff Beta SE P N eff Beta SE P N eff Beta SE P 
PLEKHA7 
rs381815 
chr11:16858844 
T 
0.297 72949 0.657 0.099 2.64E-11 41227 0.433 0.128 7.52E-04 114176 0.574 0.078 2.16E-13 
FLJ32810-
TMEM34 
rs633185 
chr11:100098748 
G 
0.317 72605 -0.571 0.097 3.90E-09 40955 -0.383 0.126 2.31E-03 113561 -0.501 0.077 6.89E-11 
ATP2B1 
rs17249754 
chr12:88584717 
G 
0.892 72147 0.960 0.120 1.51E-15 43660 0.821 0.151 5.17E-08 115807 0.906 0.094 6.02E-22 
ATXN2 
rs3184504 
chr12:110368991 
T 
0.408 67880 0.548 0.089 7.28E-10 45075 0.568 0.110 2.60E-07 112954 0.556 0.069 9.92E-16 
TBX5-TBX3 
rs10850411 
chr12:113872179 
T 
0.167 69830 0.390 0.097 5.58E-05 38735 0.360 0.127 4.60E-03 108565 0.379 0.077 8.47E-07 
CSK 
rs1378942 
chr15:72864420 
C 
0.333 70901 0.611 0.091 1.49E-11 48323 0.556 0.113 9.36E-07 119224 0.590 0.071 7.96E-17 
FES 
rs2521501 
chr15:89238392 
G 
0.633 44549 0.678 0.117 7.53E-09 30012 0.439 0.140 1.70E-03 74561 0.580 0.090 1.16E-10 
GOSR2 
rs17608766 
chr17:42368270 
T 
0.908 62617 -0.742 0.129 9.65E-09 41296 -0.708 0.161 1.03E-05 103912 -0.729 0.101 4.68E-13 
ZNF652 
rs12940887 
chr17:44757806 
T 
0.417 72137 0.342 0.091 1.63E-04 43158 0.177 0.115 1.24E-01 115295 0.279 0.071 9.03E-05 
JAG1 
rs1327235 
chr20:10917030 
G 
0.117 72799 0.320 0.088 2.58E-04 43735 0.388 0.111 5.02E-04 116534 0.346 0.069 5.11E-07 
GNAS-
EDN3 
rs6015450 
chr20:57184512 
G 
0.067 71029 0.761 0.136 2.20E-08 36000 1.006 0.181 2.93E-08 107029 0.849 0.109 5.94E-15 
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E)  Diastolic blood pressure association results for the 8 SNPs at the seven loci found to have novel association with pulse pressure and/or mean arterial pressure in Europeans in the 
present study and all 29 loci previously associated with diastolic and/or systolic blood pressure. Stage 1 and stage 2 samples are those described in Supplementary Table 1 and which were 
used for the primary pulse pressure and mean arterial pressure analyses. Loci which reach genome-wide significance (P<5x10
-8
) after the combined stage 1 and stage 2 analysis are 
highlighted in bold.   
Region 
SNP  
Chr: NCBI 36 posn 
Coded 
allele 
& freq DBP Stage 1 DBP Stage 2 DBP Combined Stage 1 + Stage 2 
    N eff Beta SE P N eff Beta SE P N eff Beta SE P 
Novel loci associated with Pulse Pressure in this study 
near FIGN 
rs13002573 
chr2:164623454 
G 
0.203 73054 -0.091 0.066 1.68E-01 43957 -0.136 0.086 1.15E-01 117011 -0.107 0.052 4.02E-02 
near CHIC2  
rs871606 
chr4:54494002 
T 
0.85 71475 0.028 0.091 7.54E-01 44067 -0.075 0.117 5.22E-01 115542 -0.010 0.072 8.85E-01 
near PIK3CG 
rs17477177 
chr7:106199094 
T 
0.717 72958 0.003 0.068 9.64E-01 39972 -0.243 0.094 9.66E-03 112930 -0.081 0.055 1.40E-01 
NOV (3' UTR) 
rs2071518 
chr8:120504993 
T 
0.167 73112 -0.161 0.063 1.09E-02 45812 -0.117 0.082 1.54E-01 118924 -0.145 0.050 3.89E-03 
near 
ADAMTS-8 
rs11222084 
chr11:129778440 
T 
0.375 67932 -0.110 0.060 6.66E-02 40414 -0.085 0.079 2.78E-01 108347 -0.101 0.048 3.44E-02 
Novel loci associated with Mean Arterial Pressure in this study 
near FIGN 
rs1446468 
chr2:164671732 
T 
0.534 69351 -0.219 0.057 1.28E-04 39653 -0.346 0.076 5.41E-06 109003 -0.265 0.046 6.88E-09 
MAP4 
(intron) 
rs319690 
chr3:47902488 
T 
0.51 59301 0.309 0.063 8.09E-07 34360 0.234 0.083 5.07E-03 93662 0.282 0.050 1.84E-08 
near ADRB1 
rs2782980 
chr10:115771517 
T 
0.198 60990 -0.294 0.067 1.05E-05 37787 -0.263 0.087 2.52E-03 98777 -0.283 0.053 9.60E-08 
 Loci previously associated with SBP and/or DBP (Ehret et al 2011) 
MTHFR-
NPPB 
rs17367504 
chr1:11785365 
G 
0.167 73894 -0.489 0.077 2.41E-10 48460 -0.573 0.097 3.41E-09 122354 -0.522 0.060 5.81E-18 
MOV10 
rs2932538 
chr1:113018066 
G 
0.825 67265 0.318 0.066 1.55E-06 38124 0.157 0.071 2.75E-02 105389 0.243 0.048 5.24E-07 
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Region 
SNP  
Chr: NCBI 36 posn 
Coded 
allele 
& freq DBP Stage 1 DBP Stage 2 DBP Combined Stage 1 + Stage 2 
    N eff Beta SE P N eff Beta SE P N eff Beta SE P 
SLC4A7 
rs13082711 
chr3:27512913 
T 
0.798 69757 -0.365 0.067 5.00E-08 39384 -0.226 0.090 1.20E-02 109141 -0.315 0.054 4.37E-09 
ULK4 
rs3774372 
chr3:41852418 
T 
0.717 73830 -0.384 0.072 9.96E-08 44031 -0.109 0.078 1.65E-01 117861 -0.257 0.053 1.17E-06 
MECOM 
rs419076 
chr3:170583580 
T 
0.436 73555 0.324 0.055 4.56E-09 41238 0.262 0.075 4.82E-04 114793 0.302 0.044 1.11E-11 
FGF5 
rs1458038 
chr4:81383747 
T 
0.3 68540 0.455 0.063 4.11E-13 40811 0.301 0.083 3.02E-04 109351 0.399 0.050 1.71E-15 
SLC39A8 
rs13107325 
chr4:103407732 
T 
0.117 63737 -0.653 0.116 1.68E-08 46581 -0.523 0.142 2.33E-04 110318 -0.601 0.090 2.11E-11 
GUCY1A3-
GUCY1B3 
rs13139571 
chr4:156864963 
C 
0.772 71353 0.376 0.066 9.93E-09 40820 0.218 0.070 2.01E-03 112172 0.302 0.048 2.97E-10 
NPR3-
C5orf23 
rs1173771 
chr5:32850785 
G 
0.525 73354 0.246 0.056 1.16E-05 43740 0.198 0.075 8.25E-03 117094 0.229 0.045 3.57E-07 
EBF1 
rs11953630 
chr5:157777980 
T 
0.342 73116 -0.249 0.057 1.37E-05 40819 -0.411 0.078 1.33E-07 113935 -0.306 0.046 3.44E-11 
HFE 
rs1799945 
chr6:26199158 
G 
0.182 71071 0.438 0.079 3.23E-08 40730 0.424 0.105 5.77E-05 111801 0.433 0.063 8.05E-12 
BAT2-BAT5 
rs805303 
chr6:31724345 
G 
0.575 73560 0.203 0.057 3.81E-04 45927 0.037 0.060 5.39E-01 119487 0.124 0.041 2.66E-03 
CACNB2(5') 
rs4373814 
chr10:18459978 
G 
0.408 71381 -0.243 0.056 1.63E-05 40016 -0.052 0.061 4.01E-01 111397 -0.155 0.041 1.83E-04 
CACNB2(3') 
rs1813353 
chr10:18747454 
T 
0.649 71792 0.354 0.060 3.47E-09 40515 0.337 0.081 3.40E-05 112307 0.348 0.048 5.38E-13 
C10orf107 
rs4590817 
chr10:63137559 
G 
0.825 72386 0.502 0.076 3.69E-11 41048 0.527 0.102 2.56E-07 113434 0.511 0.061 5.01E-17 
PLCE-1 
rs932764 
chr10:95885930 
G 
0.425 72804 0.134 0.056 1.59E-02 40896 0.175 0.077 2.25E-02 113700 0.148 0.045 1.00E-03 
CYP17A1-
NT5C3 
rs11191548 
chr10:104836168 
T 
0.942 71588 0.521 0.098 1.03E-07 43944 0.612 0.126 1.11E-06 115532 0.555 0.077 6.35E-13 
ADM 
rs7129220 
chr11:10307114 
G 
0.867 69576 -0.280 0.090 1.79E-03 41443 -0.224 0.122 6.62E-02 111020 -0.260 0.072 3.13E-04 
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Region 
SNP  
Chr: NCBI 36 posn 
Coded 
allele 
& freq DBP Stage 1 DBP Stage 2 DBP Combined Stage 1 + Stage 2 
    N eff Beta SE P N eff Beta SE P N eff Beta SE P 
PLEKHA7 
rs381815 
chr11:16858844 
T 
0.297 72936 0.374 0.063 2.31E-09 41223 0.287 0.085 7.67E-04 114159 0.344 0.050 9.98E-12 
FLJ32810-
TMEM34 
rs633185 
chr11:100098748 
G 
0.317 72600 -0.314 0.061 3.21E-07 40970 -0.248 0.083 2.90E-03 113570 -0.291 0.049 4.09E-09 
ATP2B1 
rs17249754 
chr12:88584717 
G 
0.892 72151 0.495 0.076 6.31E-11 43666 0.390 0.098 7.37E-05 115818 0.456 0.060 3.08E-14 
ATXN2 
rs3184504 
chr12:110368991 
T 
0.408 70613 0.466 0.056 1.31E-16 45068 0.390 0.072 6.86E-08 115681 0.437 0.044 7.22E-23 
TBX5-TBX3 
rs10850411 
chr12:113872179 
T 
0.167 69859 0.298 0.061 1.27E-06 38733 0.200 0.068 3.27E-03 108591 0.254 0.046 2.56E-08 
CSK 
rs1378942 
chr15:72864420 
C 
0.333 73570 0.457 0.058 2.23E-15 48324 0.351 0.074 1.91E-06 121894 0.417 0.045 4.38E-20 
FES 
rs2521501 
chr15:89238392 
G 
0.633 44344 0.426 0.074 8.57E-09 30039 0.320 0.074 1.50E-05 74382 0.373 0.052 1.01E-12 
GOSR2 
rs17608766 
chr17:42368270 
T 
0.908 62637 -0.205 0.083 1.37E-02 41363 -0.189 0.105 7.15E-02 104000 -0.199 0.065 2.28E-03 
ZNF652 
rs12940887 
chr17:44757806 
T 
0.417 72150 0.300 0.058 1.86E-07 43159 0.191 0.076 1.15E-02 115309 0.260 0.046 1.36E-08 
JAG1 
rs1327235 
chr20:10917030 
G 
0.117 72795 0.262 0.056 2.44E-06 43735 0.258 0.059 1.41E-05 116530 0.260 0.041 1.44E-10 
GNAS-EDN3 
rs6015450 
chr20:57184512 
G 
0.067 71013 0.458 0.087 1.16E-07 35992 0.615 0.122 4.41E-07 107005 0.511 0.071 4.39E-13 
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F)  All loci which were genome-wide significant (P<5x10
-8
) after meta-analysis of Stage 1 and Stage 2 for pulse pressure and mean arterial pressure, including loci previously shown to be 
associated with SBP and/or DBP. 
SNP ID gene 
Coded 
allele & 
freq Stage 1 Stage 2  Combined Stage 1 + Stage 2 
   
N 
effective Beta SE P N effective Beta SE P 
N 
effective Beta SE P 
Pulse Pressure               
rs13002573 
chr2:164623454 near FIGN 
G 
0.203 73043 -0.320 0.070 5.43E-06 44060 -0.296 0.089 8.58E-04 117102 -0.310 0.055 1.76E-08 
rs871606 
chr4:54494002 near CHIC2  
T 
0.85 71444 0.428 0.096 9.28E-06 44911 0.431 0.121 3.75E-04 116355 0.429 0.075 1.32E-08 
rs17477177 
chr7:106199094 near PIK3CG 
T 
0.717 72997 -0.460 0.071 1.19E-10 40406 -0.344 0.094 2.72E-04 113404 -0.418 0.057 2.27E-13 
rs2071518 
chr8:120504993 NOV (3' UTR) 
T 
0.167 73252 0.304 0.067 5.72E-06 46744 0.323 0.086 1.60E-04 119996 0.312 0.053 3.66E-09 
rs11222084 
chr11:129778440 near ADAMTS-8 
T 
0.375 67704 0.415 0.064 8.45E-11 40728 0.211 0.081 9.17E-03 108432 0.337 0.050 1.90E-11 
rs1173756* 
chr5:32825609 NPR3-C5orf23 
T 
0.525 73207 -0.324 0.059 4.10E-08 48938 -0.178 0.073 1.54E-02 122144 -0.267 0.046 6.85E-09 
rs9663362* 
chr10:95885167 PLCE-1 
G 
0.533 73597 -0.297 0.059 4.48E-07 44152 -0.228 0.075 2.48E-03 117750 -0.271 0.046 5.18E-09 
rs3824755* 
chr10:104585839 CYP17A1-NT5C3 
G 
0.933 73054 0.597 0.098 9.96E-10 41704 0.274 0.127 3.07E-02 114758 0.477 0.077 7.33E-10 
rs17249754 
chr12:88584717 ATP2B1 
G 
0.892 72022 0.393 0.081 1.09E-06 43967 0.391 0.102 1.25E-04 115988 0.392 0.063 5.54E-10 
rs17608766 
chr17:42368270 GOSR2 
T 
0.908 62353 -0.578 0.088 5.18E-11 42927 -0.467 0.109 1.90E-05 105280 -0.534 0.069 6.39E-15 
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SNP ID gene 
Coded 
allele & 
freq Stage 1 Stage 2  Combined Stage 1 + Stage 2 
   
N 
effective Beta SE P N effective Beta SE P 
N 
effective Beta SE P 
Mean Arterial 
Pressure               
rs1446468 
chr2:164671732 near FIGN 
 
T 
0.534 69264 -0.291 0.061 1.68E-06 39996 -0.418 0.082 3.80E-07 109259 -0.336 0.049 6.46E-12 
rs319690 
chr3:47902488 MAP4 (intron) 
T 
0.51 59137 0.306 0.066 3.88E-06 34637 0.280 0.090 1.89E-03 93774 0.297 0.053 2.69E-08 
rs2782980 
chr10:115771517 near ADRB1 
T 
0.198 61284 -0.345 0.071 1.14E-06 41537 -0.326 0.094 5.55E-04 102821 -0.338 0.057 2.46E-09 
rs17367504 
chr1:11785365 MTHFR-NPPB 
G 
0.167 73689 -0.464 0.082 1.86E-08 49370 -0.652 0.106 8.03E-10 123059 -0.534 0.065 2.18E-16 
rs13082711 
chr3:27512913 SLC4A7 
T 
0.798 69548 -0.350 0.071 8.08E-07 39910 -0.309 0.097 1.47E-03 109458 -0.336 0.057 4.62E-09 
rs1343040* 
chr3: 170668987 MECOM 
G 
0.6 
67087 -0.370 0.062 2.22E-09 35208 -0.287 0.087 1.04E-03 102295 -0.342 0.050 1.22E-11 
rs13149993* 
chr4: 81377569 FGF5 
G 
0.633 
71616 -0.415 0.063 3.29E-11 42618 -0.191 0.086 2.60E-02 114234 -0.337 0.051 2.55E-11 
rs13107325 
chr4:103407732 SLC39A8 
T 
0.117 63443 -0.670 0.127 1.34E-07 45769 -0.577 0.156 2.13E-04 109212 -0.633 0.098 1.30E-10 
rs1173771 
chr5:32850785 NPR3-C5orf23 
G 
0.525 73371 0.289 0.059 1.07E-06 43869 0.271 0.081 8.58E-04 117241 0.283 0.048 3.51E-09 
rs9313772* 
chr5: 157737035 EBF1 
T 
0.317 
70895 -0.279 0.062 6.24E-06 43103 -0.436 0.083 1.63E-07 113998 -0.335 0.050 1.48E-11 
rs198846* 
chr6: 26215442 HFE 
G 
0.858 
71385 -0.445 0.085 1.53E-07 40292 -0.539 0.115 2.55E-06 111677 -0.478 0.068 2.26E-12 
rs12258967* 
chr10: 18767965 CACNB2(3') 
G 
0.364 
67411 -0.418 0.065 1.37E-10 38762 -0.456 0.089 2.67E-07 106173 -0.431 0.052 2.05E-16 
rs4590817 
chr10:63137559 C10orf107 
G 
0.825 72693 0.544 0.082 2.98E-11 41515 0.634 0.111 1.03E-08 114208 0.576 0.066 2.14E-18 
rs11191593* 
chr10: 104929205 CYP17A1-NT5C2 
T 
0.942 
71214 0.612 0.102 1.86E-09 41171 0.749 0.140 9.01E-08 112385 0.660 0.082 1.20E-15 
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SNP ID gene 
Coded 
allele & 
freq Stage 1 Stage 2  Combined Stage 1 + Stage 2 
   
N 
effective Beta SE P N effective Beta SE P 
N 
effective Beta SE P 
rs381815 
chr11:16858844 PLEKHA7 
T 
0.297 72901 0.276 0.066 2.74E-05 41623 0.340 0.092 2.25E-04 114523 0.298 0.054 2.75E-08 
rs604723* 
chr11: 100115756 
FLJ32810-
TMEM33 
T 
0.317 
73368 -0.343 0.065 1.19E-07 45581 -0.252 0.087 3.83E-03 118949 -0.310 0.052 2.30E-09 
rs17249754 
chr12:88584717 ATP2B1 
G 
0.892 72022 0.563 0.082 6.01E-12 43975 0.545 0.107 3.74E-07 115997 0.557 0.065 1.21E-17 
rs653178* 
chr12: 110492139 ATXN2 
T 
0.592 
70336 -0.401 0.060 1.74E-11 48308 -0.475 0.076 4.97E-10 118644 -0.429 0.047 6.91E-20 
rs1378942 
chr15:72864420 CSK 
C 
0.333 73412 0.365 0.061 1.90E-09 49210 0.424 0.080 1.39E-07 122622 0.386 0.048 1.63E-15 
rs2521501 
chr15:89238392 FES 
T 
0.373 
43863 0.337 0.078 1.71E-05 30021 0.356 0.101 4.47E-04 73884 0.344 0.062 2.88E-08 
rs1327235 
chr20:10917030 JAG1 
G 
0.575 
72861 0.234 0.059 6.85E-05 43732 0.305 0.080 1.30E-04 116594 0.259 0.047 4.35E-08 
rs6026748* 
chr20: 57179210 GNAS-EDN3 
G 
0.933 
71668 -0.416 0.089 2.81E-06 40270 -0.674 0.127 1.00E-07 111938 -0.501 0.073 5.45E-12 
 
* The top SNP for this region from the previous analysis of SBP and DBP
4
  was used in place of the top SNP from this study for calculation of the risk score (see Supplementary tables 2A 
and 2B for the alternative SNP used (Ehret et al
4
) and r
2
 with the top SNP in the region from this study).
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Supplementary Table 3 Risk score analysis: association of combined risk score from sentinel SNPs associated with PP and MAP with cardiovascular and renal outcomes, and comparison of 
10-SNP PP risk score with matched 10-SNP SBP risk scores 
A) Association of combined risk score using the sentinel SNPs from 10 loci associated with pulse pressure and 22 loci associated with mean arterial pressure with dichotomous outcomes 
of hypertension, stroke, coronary artery disease (CAD), chronic kidney disease and continuous measures of hypertensive target organ damage.  
The SNPs included are listed in Supplementary Table 2F. (a) units are the unit of phenotypic measurement per SD of genetic risk score, (b) units are ln(odds ratio) per SD of genetic risk 
score, (c) units are ln(hazard ratio) per SD of genetic risk score, (d) units are ln(phenotype) per SD of genetic risk score. Estimated glomerular filtration rate (eGFR) was calculated from 
calibrated creatinine using the 4-variable Modification of Diet in Renal Disease (MDRD) Study equation. # Pulse wave velocity was inverted (1/PWV), therefore a negative value is 
indicative of higher pulse wave velocity. 
    Pulse Pressure (10 SNPs) Mean Arterial Pressure (22 SNPs)   
Disease endpoints Source Effect SE P value Effect SE P value N case/control 
    (per SD of genetic risk score) (per SD of genetic risk score)   
Incident heart failure  
(c)
 
CHARGE Consortium  
Heart Failure 
Working Group -0.001 0.020  0.96 0.022 0.021 0.29 2,526/18,400 
Incident ischemic stroke 
(c)
 NEURO-CHARGE 0.074 0.033 0.03 0.079 0.036 0.03 1,164/18,058 
Incident all stroke 
(c)
 NEURO-CHARGE 0.083 0.024 4.87E-04 0.071 0.023 1.93E-03 1,544/18,058 
Prevalent CAD 
(b)
 CARDIoGRAM 0.030 0.010 1.66E-03 0.070 0.010 4.67E-12 22,233/64,726 
Prevalent CAD 
(b)
 C4D PROCARDIS 0.033 0.021 0.13 0.145 0.022 2.66E-11 5720/4381 
Prevalent CAD 
(b)
 C4D HPS 0.017 0.026 0.51 0.048 0.027 0.07 2704/2887 
Prevalent CAD – combined 
(b)
 
CARDioGRAM & 
C4D 0.029 0.008 4.26E-04 0.081 0.009 4.02E-20  30,657/71,911 
Prevalent chronic kidney disease 
(b)
 CKDGen 0.034 0.015 0.02 -0.007 0.015 0.66 5,807/61,286 
Prevalent microalbuminuria 
(b)
 CKDGen 0.020 0.018 0.25 -0.007 0.019 0.71 3,698/27,882 
Hypertension 
(b)
 DECODE    0.106 0.024 7.93E-06  0.118 0.015 5.12E-16  6788/24960 
Continuous measures of target organ damage              
Left ventricular mass [g] 
(a)
 EchoGen 0.309 0.304 0.31 0.720 0.313 0.02 NA 
Left ventricular wall thickness [mm] 
(a)
 EchoGen 0.002 0.002 0.20 0.007 0.002 2.07E-04 NA 
Serum creatinine 
(d)
 KidneyGen 0.000 0.001 0.52 -0.0011 0.0020 0.58 NA 
eGFR (4 parameter MDRD equation) 
(d)
 CKDGen -0.002 0.001 0.07 -0.0003 0.0009 0.73 NA 
Urinary albumin/creatinine ratio 
(d)
 CKDGen 0.004 0.006 0.56 -0.0008 0.0064 0.90 NA 
Pulse wave velocity
(a)# 
AortaGen -0.018 0.007 0.01     
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B) Comparison of 10-SNP PP risk score with matched 10-SNP SBP risk scores.  
 The 1000 permutations of 10-SNP SBP risk scores (matched with the 10-SNP PP risk score on SBP effects) generate an empirical distribution of P values for the SBP risk score for each 
outcome, used as a null distribution to test the hypothesis of no difference between the PP and SBP risk scores. Two-tailed empirical P values (shown in table) for this test are derived by 
comparing the PP risk score P values with the SBP risk score empirical P value distribution. *median P value from the 1000 permutations of 10-SNP SBP risk scores for each outcome, 
indicating association of the (average) SBP risk score with each outcome. Outcomes with Empirical P < 0.05 are shown in bold. 
(a)
Of the 1000 permutations there were no SBP risk score P 
values as large as the corresponding PP score P value of 0.13. Estimated glomerular filtration rate (eGFR) was calculated from calibrated creatinine using the 4-variable Modification of 
Diet in Renal Disease (MDRD) Study equation. CAD: coronary artery disease. 
 
Disease endpoints  Source 
Pulse Pressure  
P value 
Systolic Blood Pressure  
Median
*
 P value 
Difference between risk scores: 
Empirical P value (2-tailed) 
Incident heart failure  
CHARGE Consortium  Heart Failure Working 
Group 
0.96 0.47 0.07 
Incident ischemic stroke NEURO-CHARGE 
0.03 0.45 0.03 
Incident all stroke  NEURO-CHARGE 
4.87E-04 0.07 0.06 
Prevalent CAD  CARDIoGRAM 
1.66E-03 0.12 0.28 
Prevalent CAD  C4D PROCARDIS 
0.13 6.70E-06 0
(a) 
Prevalent CAD  C4D HPS 
0.51 0.16 0.32 
Prevalent CAD – combined  CARDioGRAM & C4D 
4.26E-04 0.18 0.13 
Prevalent chronic kidney disease  CKDGen 
0.02 0.42 0.06 
Prevalent microalbuminuria  CKDGen 
0.26 0.54 0.38 
Continuous measures of target organ 
damage   
      
Left ventricular mass [g]  EchoGen 
0.31 0.09 0.52 
Left ventricular wall thickness [mm]  EchoGen 
0.20 0.01 0.06 
Serum creatinine  KidneyGen 
0.53 0.29 0.64 
eGFR (4 parameter MDRD equation)  CKDGen 
0.07 0.24 0.36 
Urinary albumin/creatinine ratio CKDGen 
0.56 0.55 0.96 
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Supplementary Note 
 
Phenotype modelling  
In the Stage 1 studies, in individuals taking antihypertensive therapies, SBP and DBP were imputed 
by either adding 15 mm Hg to measured SBP and 10 mm Hg to measured DBP, or by adding 10 mm 
Hg to measured SBP and 5 mm Hg to measured DBP. In Stage 2, all studies added 15 mm Hg to 
measured SBP and 10 mm Hg to measured DBP in individuals taking anti-hypertensive therapies. The 
different constants used for this imputation step did not impact on PP and had little impact on MAP 
in Stage 1 only. 
PP and MAP were derived from these imputed SBP and DBP values as follows: 
 PPimputed = SBPimputed - DBPimputed 
 MAPimputed = (2 DBPimputed + SBPimputed)/3 
 
PP and MAP were adjusted for sex, age, age2 and body mass index (BMI) along with additional 
covariates necessary to control for population stratification as necessary. 
Genotype-phenotype association analysis 
Genotype-phenotype association of PP and MAP were carried out under an additive model using 
software as described in Supplementary Table 1B. For a subset of studies which already had GWAS 
data for SBP and DBP, the effect estimates and standard errors for SBP and DBP were used to derive 
the effect estimates and standard errors for PP and MAP as follows: 
 
Where β is the GWAS effect size estimate for the subscripted trait, s is the corresponding standard 
error and rSD is the phenotypic correlation of SBP and DBP. Studies comprising 25% of the total 
sample size used this method (Supplementary Table 1B). All other studies estimated PP and MAP 
directly from SBP and DBP as described above and undertook association testing on these values.  
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Selection of SNPs for follow-up in Stage 2 
All SNPs with P<1x10-5 for association with either PP or MAP (or both) were divided into 
independent regions based on LD and the most significant SNP was selected from each region.  A 
total of 67 loci were identified. Of these, 45 loci had not previously shown association with SBP 
and/or DBP  and 47 SNPs were selected for follow-up: for one SNP with a low N effective, a proxy 
was also included and for one locus which showed association with both PP and MAP, the sentinel 
SNPs were close together but statistically independent and so both were taken forward to Stage 2.  
For all regions that showed association with PP and/or MAP and which had previously shown 
association with SBP or DBP (22 loci), the sentinel SNP for PP and MAP and the previously reported 
SNP for SBP and DBP were followed up (44 SNPs).  
In addition, 8 SNPs from 7 regions which do not show association with MAP or PP in our study, but 
which previously showed association with SBP and/or DBP were also included. 
Loci showing nominal
association (P<1x10-5 )
with PP and/or MAP
47SNPs
45 loci
44SNPs
22 loci
Loci which previously showed
association with SBP and/or
DBP
8SNPs
7 loci
99 SNPs followed up in stage 2
* This group includes both the
sentinel SNP for each locus
associated with MAP or PP, and
also the sentinel SNP(s) from
the original studies reporting
the association with SBP and /or
DBP for each locus.
*
 
 
Risk score analyses using multi-SNP predictors 
Risk scores can be calculated in the following way: Using a set of m SNPs, for the i-th SNP in the j-th 
individual denote xij as the 0/1/2 coded genotype (for directly genotyped markers) or expected allele 
count (which takes real values between 0.0 and 2.0 for imputed markers). Using results from Stages 
1+2, define the set of regression coefficients to be w1, w2, ..., wm. Then the risk score for subject j is 
defined to be 
(1) s+ = s0 + w1 x1j + w2 x2j + ... + wm xmj, 
 
where s0 is the intercept. We specify the coefficients w1, w2, ..., wm to be the effect sizes, in mmHg 
per coded allele, estimated in single SNP analyses of either PP or MAP in Stages 1+2. 
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When considering multiple SNPs that are in linkage equilibrium with each other, and small effect 
sizes per SNP, effect sizes estimated jointly for all SNPs using a multiple regression model are 
effectively identical to those estimated in a series of single SNP regression models. Thus regression 
on the risk score can be reconstructed from regressions on each of the m SNPs in turn, without 
further access to individual-level data. 
 
The calculations involved are of the same type as for meta-analysis; the coefficient of the risk score 
is the mean of the per-SNP regression coefficients, where each is weighted by its corresponding wi 
(in our analysis, the observed effect of the SNP on PP or MAP defined from Stage1+2 results). The 
estimated variance of the risk score is given by similarly weighting the estimated variances (squared 
standard errors) of each per-SNP regression coefficient. The assumption of zero LD between SNPs 
ensures that these contributions are independent. Importantly, as with inverse-variance weighted 
meta-analysis, in large samples this procedure gives valid P-values under the null, i.e. when there is 
no relationship between the “lookup” phenotype and any variants at the SNPs contributing to the 
risk score. 
 
Using SNP-specific results in this way, we estimated and tested the coefficient of the risk score in 
independent “lookup” results using linear regression for continuous phenotypes, logistic regression 
for binary phenotypes, and proportional hazards regression for time-to-event phenotypes. These 
estimates and tests inherit the covariate adjustment performed in the original SNP-specific analysis. 
Results are presented in Supplementary Table 3A. 
 
Comparison of PP and SBP risk scores  
To investigate whether the association between the PP variants and cardiovascular and renal 
outcomes is different to that expected from their association with SBP, we compared the 10-SNP PP 
risk score (weighted by PP effect sizes) to a series of 10-SNP SBP risk scores (weighted by SBP effect 
sizes). Each SBP risk score comprised 10 SNPs selected from the 26 blood pressure SNPs from Ehret 
et al. (2011) and the present study that are associated with SBP but not PP. SNPs selected for the 
SBP risk scores are constrained to have similar sized effects for SBP as those of the 10 PP SNPs; this 
was in order to provide a like-for-like comparison of PP and SBP scores in terms of SBP effect. The 10 
PP SNPs have an average (absolute) effect on SBP (Stages 1 and 2 of the present study) of 0.5452 
mmHg per coded allele, thus a total effect across the 10 risk alleles of 5.452 mmHg. So for 
comparison, the SBP risk scores were calculated for sets of 10 SBP variants with a total additive 
(absolute) effect on SBP in the range 5.447-5.557 mmHg. Thus the sum of the weights, wi for i={1, ... 
,10}, for each SBP risk score was between 5.447 and 5.557. This range was chosen to closely match 
the total SBP effect of the 10 PP SNPs, while ensuring that each permutation of 10 SBP SNPs was not 
restrictive in terms of SNP selection. One thousand permutations (each with a unique set of SNPs) of 
the SBP risk scores were calculated in order to generate a distribution of SBP risk score results. The 
P- value associated with each outcome from the PP risk score is then converted to an empirical P- 
value using this distribution of SBP risk score P-values. The empirical P-values (presented in 
Supplementary Table 3B) correspond to two-tailed tests of the null hypothesis of no difference 
between the association of the PP risk score with each outcome and the SBP risk score. Outcomes 
for which data were available for all SNPs shown to be associated with blood pressure in Ehret et al1 
and the present study were tested. 
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Functional SNPs in linkage disequilibrium with novel PP and MAP SNPs 
Using SNAP7, functional SNPs (i.e. which are synonymous or non-synonymous or which lie within a  
3’UTR, 5’UTR or regulatory region) correlated (r2>0.3) with the sentinel SNP in each of the novel loci 
were identified. SNP rs11222084 has r2=0.4 with a non-synonymous SNP in ADAMTS8. SNP 
rs2071518 has r2>0.55 with 6 other SNPs in the 3’UTR of NOV and r2=0.35 with a synonymous SNP in 
ENPP2. SNP rs319690 has r2=0.74 with two non-synonymous SNPs in  MAP4 and r2=0.64 with two 
SNPs in CSPG5, one of which lies within the 5’UTR and the other being a non-synonymous SNP 
previously associated with schizophrenia8. 
RNA sequence expression analysis 
Remnant aortic tissue was obtained from donor kidneys after transplantation. 
Total RNA was isolated from ten aorta samples according to a phenol-chloroform extraction. The 
selection of four samples for direct mRNA sequencing was based on Lab-on-a chip quality control 
(QC) and real-time PCR of the household gene GPDH. Sample characteristics and QC are presented 
below: 
Sample ID Sex Age RINa Ctb 
1 female 68 6.2 25.5 
2 male 53 5.8 24.2 
3 male 35 3.5 24.1 
4 female 19 7.5 36.3 
a RNA Integrity Number measured using lab-on-a-chip 
b relative copy number of GPDH, measured using real time PCR.  
 
Total mRNA was sequenced directly using a Helicos Helisphere according the manufacturer’s 
protocols (helicosbio.com ) at the Leiden Genome Technology Center (www.LGTC.nl). Helicos reads 
(length 25 to 57) were aligned to the h19 reference sequence with the Helicos alignment software. 
Automated annotation of tags relevant to transcript positions was based on BioMart 
(www.ensembl.org). Absolute read count per transcript were calculated by dividing the total 
coverage of all the covered nucleotides in the exonic regions of a transcript by the number of 
nucleotides covered and expressed as “reads per kilo base per million” (RpKM). Wiggle tracks 
(truncated at coverage of three) from each individual sample as well as cumulative wiggle files were 
generated for viewing in the UCSC genome browser (www.genomes.ucsc.edu) (Supplementary 
Figures 3A and 3B). Transcripts which were covered by reads located in only very confined exonic -or 
intronic regions were regarded as not expressed. 
Selection of negative and positive expressed control transcripts was based on literature -and 
database search (genecards.org) of genes with tissue specific expression. The adipokines, leptin (LEP) 
and adiponectin (ADIPOQ) were expected to be expressed solely in adipose tissues. Furthermore, 
apolipoprotein 5 (APOAV) was expected to be expressed primarily in the liver. Epidermal growth 
factor receptor (EGFR), actin alpha 2 (ACTA2), collagen type IV alpha 1 (COL4A1) and elastin (ELN) 
were expected to be highly expressed in aortic tissue. 
56 
 
The relative read counts for negative controls were below the filtering threshold value of 3 RpKM 
and were therefore set to 0 (data not shown). Relative counts of positive controls ranged however 
from 10 for EGFR to 1232 for ACTA2 (Supplementary Figure 3C). The relative read count for the 
pulse-pressure top hits ADAMTS15, ADAMTS8, NOV and PDGFRA (near 3’ CHIC2) were 8, 9, 287, and 
22, respectively, while PIK3CG and FIGN were not expressed in aorta (Supplementary Figure 3C and 
c). From the MAP top hits, only MAP4 was detectably expressed in aorta at 99 RpKM, while 
expression of FIGN, GRB14, and ADRB1 was not detectable (Supplementary Figure 3D).  
 
eQTL analyses 
For each of the 8 sentinel genome-wide significant blood pressure SNPs (Table 1), all proxy SNPs 
with r2>0.6 were determined in HapMap CEU. All sentinel SNPs and their proxies were searched 
against a collected database of expression quantitative trait locus (eQTL) results, including the 
following tissues: fresh lymphocytes9, fresh leukocytes10, leukocyte samples in individuals with Celiac 
disease11, lymphoblastoid cell lines (LCL) derived from asthmatic children12, HapMap LCL from 3 
populations13, a separate study on HapMap CEU LCL14, fibroblasts, T cells and LCL derived from cord 
blood15, 2 studies on peripheral blood monocytes 16,17, CD4+ lymphocytes18, adipose and blood 
samples19, 2 studies on brain cortex16,20, 3 large studies of brain regions including prefrontal cortex, 
visual cortex and cerebellum (Emilsson, personal communication), a study of cerebellum, frontal 
cortex, temporal cortex and caudal pons21, a separate study on prefrontal cortex22, liver23, and 
osteoblasts24. The collected eQTL results met criteria for statistical significance for association with 
gene transcript levels as described in the original papers. 
 The genome-wide significant SNP associated with MAP, rs2782980, was also significantly associated 
with transcript levels of ADRB1 in visual cortex tissue from Alzheimer cases and controls (P=3.2x10-9), 
and in visual cortex tissue and prefrontal cortex tissue from Alzheimer cases only (P=3.4x10-5 and 
P=5.4x10-7, respectively) (Supplementary Figure 4A).  
A proxy for SNP rs319690, rs319689 (r2=0.737 with rs319690, association with MAP:P=2.7x10-8) 
showed significant association with transcript levels of ZNF589 in monocytes (P=2.9x10-12). An 
independent database of eQTL results from monocytes was also interrogated (see Cardiogenics 
consortium study description). This analysis replicated the finding in monocytes and gave a 
significant association with another proxy SNP for rs319690 (rs319684 r2=0.74) with ZNF589 
expression (Supplementary Figure 4B). 
Two additional proxy SNPs for rs319690, rs1301913 and rs11130148 (each with r2=0.644 with 
rs319690 and showing genome-wide significant association, P=2.7x10-8, with MAP) showed 
significant association with transcript levels of DHX30 in lymphoblastoid cell lines (P=1.3x10-8 and 
P=1.6x10-8, respectively), with rs11130148 also showing significant association with transcript levels 
of CDC25A in adipose tissue (P=9.2x10-5) and ZNF589 in blood (P=4.2x10-4). A proxy SNP for 
rs2071518, rs7816205 (r2=0.714 with rs2071518, association with PP: P=3.7x10-9) showed significant 
association with transcript levels of ENPP2 in cerebellum tissue (P=9.4x10-5). 
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Study Descriptions 
AGES Reykjavik  
The Age Gene/Environment Susceptibility-Reykjavik Study originally comprised a random sample of 
30,795 men and women born in 1907-1935 and living in Reykjavik in 1967. A total of 19,381 people 
attended, resulting in a 71% recruitment rate. The study sample was divided into six groups by birth 
year and birth date within month. One group was designated for longitudinal follow up and was 
examined in all stages; another was designated as a control group and was not included in 
examinations until 1991. Other groups were invited to participate in specific stages of the study. 
Between 2002 and 2006, the AGES-Reykjavik study re-examined 5,764 survivors of the original 
cohort who had participated before in the Reykjavik Study25. The midlife data blood pressure 
measurement was taken from stage 3 of the Reykjavik Study (1974-1979), if available. Half of the 
cohort attended during this period. Otherwise an observation was selected closest in time to the 
stage 3 visit. The supine blood pressure was measured twice by a nurse using a mercury 
sphygmomanometer after 5 minutes rest following World Health Organization recommendations 26. 
Individuals with previous MI were excluded from the analyses (N=12). 
ARIC 
 The Atherosclerosis Risk In Communities Study is a population-based prospective cohort study of 
cardiovascular disease sponsored by the National Heart, Lung, and Blood Institute (NHLBI). ARIC 
included 15,792 individuals aged 45-64 years at baseline (1987-89), chosen by probability sampling 
from four US communities27. Cohort members completed four clinic examinations each spread over 
about three years, conducted approximately three years apart between 1987 and 1998. The data 
used in this study are from the first visit in 1987-1989. A detailed study protocol is available on the 
ARIC study website (http://www.cscc.unc.edu/aric). Blood pressure was measured using a 
standardized Hawskley random-zero mercury column sphygmomanometer with participants in a 
sitting position after a resting period of 5 minutes. The size of the cuff was chosen according to the 
arm circumference. Three sequential recordings for systolic and diastolic blood pressure were 
obtained; the mean of the last two measurements was used in this analysis, discarding the first 
reading. Blood pressure lowering medication use was recorded from the medication history. Outliers 
(>4SD from the mean) with respect to the systolic or diastolic blood pressure distribution were 
excluded from the analysis. For this study the sample was restricted to individuals of European 
descent by self report and principal component analysis using genome-wide genotypes. 
ASPS 
The Austrian Stroke Prevention study is a single center prospective follow-up study on the effects of 
vascular risk factors on brain structure and function in the normal elderly population of the city of 
Graz, Austria. The procedure of recruitment and diagnostic work-up of study participants has been 
described previously28. A total of 2007 participants were randomly selected from the official 
community register stratified by gender and 5 year age groups. Individuals were excluded from the 
study if they had a history of neuropsychiatric disease, including previous stroke, transient ischemic 
attacks, and dementia, or an abnormal neurologic examination determined on the basis of a 
structured clinical interview and a physical and neurologic examination. During two study panels 
between September 1991 and March 1994 and between January 1999 and December 2003 an 
extended diagnostic work-up including MRI and neuropsychologic testing was done in 1076 
individuals aged 45 to 85 years randomly selected from the entire cohort. Since 1992 blood was 
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drawn from all study participants for DNA extraction. They were all European Caucasians.  There 
were 767 participants included in the present study after exclusion those with recognized 
myocardial infarction and congestive heart failure at the time of blood pressure measurement. 
Blood pressure is measured in sitting position on two occasions. The first time after about 10 
minutes the participant arrived on the left and on the right side, and at a second time at the end of 
the physical examination only on the left side. The mean of these 3 measurements are used for 
imputation. 
B58C-T1DGC  
The British 1958 Birth Cohort – Type 1 Diabetes Genetics Consortium is a sample from the national 
population-based sample followed periodically from birth to age 44-45 years 
(http://www.b58cgene.sgul.ac.uk/collection.php) and 2,580 individuals were included in this 
analysis. Blood pressure was recorded using the Omron 705CP machine three times, seated. The 
average of three readings was used for the analysis. 
B58C-WTCCC  
The British 1958 Birth Cohort – Wellcome Trust Case Control Consortium is a second sample from 
the national population-based sample followed periodically from birth to age 44-45 years 
(http://www.b58cgene.sgul.ac.uk/collection.php); 1,473 individuals were included in the analysis 
and are distinct from individuals included in the B58C-T1DGC cohort. Blood pressure was recorded 
using the Omron 705CP machine three times, seated. The average of three readings was used for the 
analysis. 
BHS  
The Busselton Health Study includes a series of seven cross sectional population health surveys of 
adult residents of the Shire of Busselton in the South-West of Western Australia, undertaken 
between 1966 and 1990. A cross-sectional community follow-up study in 1994-1995 included the 
collection of blood for DNA extraction for all survivors of previous surveys. A total of 4,554 
individuals participated in this follow-up. Data from a subset of 1038 unrelated individuals with 
complete data were analysed for the present study. BP was measured in the 1994-1995 follow-up 
study using a standard mercury sphygmomanometer (Baumanometer, New York) as described in 29. 
The participants were asked to refrain from caffeine for 12 hours and to not smoke prior to 
attending the survey. Three BP readings were recorded on the participant’s survey chart to the 
nearest 2 mmHg and the average of the readings was used for the analyses. 
BLSA  
The Baltimore Longitudinal Study of Ageing is an ongoing prospective study of human ageing which 
started in 195830. The study recruited volunteers predominantly from Washington DC and Baltimore, 
MD, USA. Healthy volunteers aged >17 years were recruited; only European-origin individuals were 
included in the analysis, there were no other exclusion criteria. Blood pressure was measured using 
a mercury sphygmomanometer in the seated position, the average of the 2nd and 3rd readings were 
recorded for both the right and left arm and used for the analyses. 
CHS 
The Cardiovascular Health Study is a population-based cohort study of risk factors for cardiovascular 
disease in adults 65 years of age or older conducted across four field centres. The original 
predominantly white cohort of 5,201 persons was recruited in 1989-1990 from random samples of 
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the Medicare eligibility lists and an additional 687 African-Americans were enrolled in 1992-93 for a 
total sample of 5,888. Details of the study design are summarized elsewhere 31. A total of 1,908 
persons were excluded from the study sample due to prevalent coronary heart disease (N=1195), 
congestive heart failure (N=86), peripheral vascular disease (N=93), valvular heart disease (N=20), 
stroke (N=166), or transient ischemic attack (N=56). Participants with missing BMI (N=10) or BP 
measurements (N=8) were also excluded. Research staff with central training in blood pressure 
measurement assessed repeated right-arm seated systolic and diastolic blood pressure levels at 
baseline with a Hawksley random-zero sphygmomanometer. Means of the repeated blood pressure 
measurements from the baseline examination from 3,277 CHS subjects of European ancestry were 
used for the analyses. 
CoLaus 
The Cohorte Lausannoise is a population-based study aimed at assessing the prevalence and 
molecular determinants of cardiovascular risk factors in the population of Lausanne, Switzerland32. 
Participants in the study (4,969) were randomly selected from the population register of Lausanne in 
2003 (N=56,694, aged 35-75 years). All individuals were of European origin, defined as having both 
parents and grandparents born in a defined list of European countries. Blood pressure was 
measured using the Omron HEM-907 machine, in the seated position. Three measures were taken 
on the left arm; the mean of the last two measures was used in the analyses. 
CROATIA-Korcula 
The KORCULA study sampled Croatians from the Adriatic island of Korcula (N=969), between the 
ages of 18 and 88. The fieldwork was performed in 2007 in the eastern part of the island, targeting 
healthy volunteers from the town of Korcula and the villages of Lumbarda, Žrnovo and Racišce33. 
Over 150 quantitative traits were measured to each participant. Blood pressure was measured using 
standard procedures, briefly, the subject was seated in a quiet room, and they were advised to not 
have done any exercise, or have been exposed to the cold, eaten, or smoked for half an hour prior to 
the recording. Following 5 minutes of rest, blood pressure was recorded twice during the 
examination and the mean of the two reading were used for the analyses. 
CROATIA-Split 
The SPLIT study is a cross-sectional study that samples Croatians from the town of Split (N=1012), 
between the ages 18 and 85. The sampling was performed between 2008 and 201034. A wide range 
of phenotypic measurements is available. Blood pressure was measured using standard procedures. 
Briefly, the subject was seated in a quiet room and they were advised to not have done any exercise, 
or have been exposed to the cold, eaten, or smoked for half an hour prior to the recording. 
Following 5 minutes of rest, blood pressure was recorded twice during the examination and the 
mean of the two reading were used for the analyses. 
CROATIA-Vis  
The CROATIA-Vis (EUROSPAN) study includes Croatians, aged 18 to 93 years, who were recruited 
during 2003 and 2004 in a population-based study in the villages of Vis and Komiza on the Dalmatian 
island of Vis, Croatia34,35. Biochemical and physiological measurements were performed, detailed 
genealogies reconstructed, questionnaire of lifestyle and environmental exposures collected, and 
blood samples and lymphocytes extracted and stored for further analyses. Blood pressure was 
measured using standard procedures, briefly, the subject was seated in a quiet room, and they were 
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advised to not have done any exercise, have been exposed to cold, eaten, or smoked for half an hour 
prior to the recording. Following 5 minutes of rest, blood pressure was recorded twice during the 
examination and the mean of the two reading were used for the analyses. 
DGI 
The Diabetes Genetics Initiative (DGI) is a type 2 diabetes (T2D) case-control study of Swedish and 
Finnish individuals matched on age, gender and BMI36. GWAS data from 1,467 normoglycemic male 
and female controls were included in these analyses. Blood pressure traits were the average of two 
seated measurements using a mercury sphygmomanometer. 
EGCUT 
Estonian Genome Center, University of Tartu (EGCUT); The Estonian cohort is from the population-
based biobank of the Estonian Genome Project of University of Tartu. The whole project is 
conducted according to the Estonian Gene Research Act and all participants have signed the broad 
informed consent37 (www.geenivaramu.ee). The current cohort size is over 48,000, from 18 years of 
age and up, which reflects closely the age distribution in the adult Estonian population. Subjects are 
recruited by the general practitioners (GP) and physicians in the hospitals were randomly selected 
from individuals visiting GP offices or hospitals. Each participant filled out a Computer Assisted 
Personal interview during 1-2 hours at a doctor’s office, including personal data (place of birth, 
place(s) of living, nationality etc.), genealogical data (family history, four generations), educational 
and occupational history and lifestyle data (physical activity, dietary habits, smoking, alcohol 
consumption, women´s health, quality of life). Anthropometric and physiological measurements 
were also taken. GWAS was performed on randomly selected individuals38 with the Illumina 
HumanHapCNV370 or OmniExpress array, according to the Illumina protocol (www.illumina.com) in 
the Estonian Biocenter Genotyping Core Facility. 
EPIC-Norfolk 
The European Prospective Investigation of Cancer is a population-based cohort study of 25,663 
Europid men and women aged 39-79 years recruited in Norfolk, UK between 1993 and 199739. 2,100 
randomly selected control subjects were chosen from a BMI study in which genome-wide 
genotyping data had been obtained. Blood pressure was measured using the Accutorr oscillometric 
BP machine; the mean of two readings was taken and used in the analysis. 
ERF 
The ERF (EUROSPAN) study is a family based study which includes over 3,000 participants 
descending from 22 couples living in the Rucphen region, the Netherlands, in the 19th century. All 
descendants were invited to visit the regional clinical research centre where they were examined 
and a fasting blood sample was drawn. All participants filled out a questionnaire on risk factors. The 
participants included in these analyses consisted of the first series of participants. 
Fenland 
The Fenland Study is an ongoing population-based cohort study (started in 2005) designed to 
investigate the association between genetic and lifestyle environmental factors and the risk of 
obesity, insulin sensitivity, hyperglycaemia, and related metabolic traits in men and women aged 30 
to 55 years. Potential volunteers were recruited from general practice sampling frames in the 
Fenland, Ely, and Cambridge areas of the Cambridgeshire Primary Care Trust in the U.K. Exclusion 
criteria for the study were: prevalent diabetes, pregnant, and lactating women, inability to 
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participate including terminal illness, psychotic illness, or inability to walk unaided. Currently, the 
study comprises more than 3,000 participants of whom the first 1,500 volunteers with complete 
anthropometric data were genotyped and included in the current analyses. All participants were 
measured at the MRC Epidemiology Unit Clinical Research Facilities in Ely, Wisbech and Cambridge. 
Blood pressure measurements were taken with an Accutorr automated sphygmomanometer using 
the average of three measurements made at one-minute intervals with the participant seated for 5 
minutes prior to measurement. Of the 1,500individuals that were genotyped 98 individuals were 
excluded as their genotyping data did not meet the quality control criteria applied such that 1,402 
individuals were included in the genome-wide association analyses. 
FHS 
The Framingham Heart Study began in 1948 with the recruitment of an original cohort of 5,209 men 
and women (mean age 44 years; 55 percent women). In 1971 a second generation of study 
participants was enrolled; this cohort consisted of 5,124 children and spouses of children of the 
original cohort. The mean age of the offspring cohort was 37 years; 52 percent were women. A third 
generation cohort of 4,095 children of offspring cohort participants(mean age 40 years; 53 percent 
women) was enrolled beginning in 2002. Details of study designs for the three cohorts are 
summarized elsewhere40-42. At each clinic visit, a medical history was obtained with a focus on 
cardiovascular content, and participants underwent a physical examination including measurement 
of height and weight from which BMI was calculated. Systolic and diastolic blood pressures were 
measured twice by a physician on the left arm of the resting and seated participant using a mercury 
column sphygmomanometer. Pressures were recorded to the nearest even number. The means of 
two separate systolic and diastolic blood pressure readings at the first clinic examination of each 
cohort were used for this GWAS analyses. For a subset of offspring cohort participants only one 
measurement was obtained. Individuals under 20 years of age, those who had a myocardial 
infarction, or congestive heart failure were excluded from the analyses because those conditions 
may affect blood pressure levels. 
FUSION  
The Finland-United States Investigation Of NIDDM Genetics study aims to discover variants 
predisposing to type 2 diabetes (T2D) and T2D-related quantitative traits 
(http://fusion.sph.umich.edu/)43,44. The FUSION GWAS sample includes 1,161 Finnish T2D cases and 
1,174 normal glucose tolerant (NGT) controls and 122 offspring of case/control pairs (1T2D, 119 
NGT, 2 with impaired glucose tolerance). GWAS data from the controls and NGT offspring were used 
for these analyses. The blood pressure trait was the average of two seated measurements using a 
mercury sphygmomanometer after 5 minutes of rest45. FUSION analyses were adjusted for birth 
province. 
InChianti 
The Invecchiare in Chianti study is a representative population-based study of older people living in 
the Chianti area of Tuscany, Italy46. All participants were >21 years of age and of white European 
origin. Blood pressure was measured using a mercury sphygmomanometer in the supine position; 
the average of the 2nd and 3rd readings was used for the analysis. 
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INGI CARL 
The Carlantino cohort comprehends about 900 samples from an isolated village of southern Italy 
(Carlantino). Genotyping data for 679 people is available, of these 521 had also phenotypic data. 
Mean age of the participants was 45.9 years (SD 19.920). Ethics approval was obtained from the 
Ethics Committee of the Burlo Garofolo children hospital in Trieste. Written informed consent was 
obtained from every participant of the study. Blood pressure for each participant was measured 3 
times for each arm. Systolic and diastolic blood pressure was calculated taking the higher value 
between the mean of the three readings at each arm. All samples were typed with illumina 370k 
CNV chip (Illumina, San Diego, USA). Imputation of genotypes was carried out using the software 
MACH. The following QC filters were applied prior to imputation: call rate > 95% , MAF ≥ 1% , HWE 
P-value ≥ 10-4 and per SNP call rate ≥ 90%. 266,389 SNPs where then used as backbone for the 
imputation. The total number of SNPs used for the analysis was 2,599,375. 
INGI FVG 
The Friuli Venezia Giulia cohort comprehends about 1300 samples from 5 isolated villages of Friuli 
Venezia Giulia, a region of northern Italy. The villages are: Resia, Illegio, San Martino del Carso, 
Erto/Casso, Clauzetto. Genotyping data for 1266 people is available, of these 1046 had also 
phenotypic data. Mean age of the participants was 51.7 years (SD 16.4). Because of the particular 
structure of this cohort we used both molecular kinship and the village as covariate for the statistical 
analysis. Ethics approval was obtained from the Ethics Committee of the Burlo Garofolo children 
hospital in Trieste. Written informed consent was obtained from every participant to the study. 
Blood pressure for each participant was measured 3 times for each arm. Systolic and diastolic blood 
pressure was calculated taking the higher value of the mean of the three readings at each arm.        
All samples were typed with illumina 370k CNV chip (Illumina, San Diego, USA). Imputation of 
genotypes was carried out using the software MACH. The following QC filters were applied prior to 
imputation: call rate > 95%, MAF ≥ 1%, HWE P-value ≥ 10-4 and per SNP call rate ≥ 90%. 276,271 SNPs 
where then used as backbone for the imputation. The total number of SNPs used for the analysis 
was 2,599,375. 
INGI Val Borbera 
Val Borbera project was initiated in 2005 and represents the collection of phenotypic and genotypic 
data from a geographically isolated population of North West Italy living in the Val Borbera Valley in 
Piedmont. Inhabitants of the valley were invited to participate in the study by public advertisements 
through local authorities, televisions and newspapers as well as local physicians and mailings. 
Meetings were organized in all villages to present the project and its aims. The importance of the 
participation of entire families was underscored in all instances, nevertheless all people that 
volunteered to participate were included in the study, providing they had at least one grand parent 
from the valley. The study, including the overall plan and the informed consent form was reviewed 
and approved by the institutional review boards of San Raffaele Hospital in Milan and by the Regione 
Piemonte ethical committee. Information and biological samples were obtained  from 1803 
inhabitants between 18 and 102 years of age47. 1664 DNAs were genotyped with the genome-wide 
370k Illumina chip. Only individuals aged 18 years or older were eligible. Blood pressure was 
measured with a mercury sphygmomanometer. SBP and DBP were the average of four 
measurements done with subjects in a seated position in a quiet environment. 
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KORA S3 
The KOoperative Gesundheitsforschung in der Region Augsburg (third survey: S3/F3) is an 
epidemiological cohort recruited from the general population of Augsburg, Germany in 1994-
199548,49. A subset of this survey (1,644 subjects) were genotyped using the Affymetrix 500K array 
(http://epi.helmholtz-muenchen.de/kora-gen/). In this study subjects with BMI<35 kg/m2 were 
included; diabetics were excluded. Final number of subjects entering the association analysis with 
blood pressure was 1,503. Blood pressure was measured using a random zero sphygmomanometer 
in the seated position at the first examination cycle. Three measurements were taken at least three 
minutes apart and the numbers entering the database were the mean of the last two 
measurements. 
KORA F4 
The KORA S4 survey, a population-based sample from the general population living in the region of 
Augsburg, Southern Germany, was conducted in 1999/2001. The standardized examinations applied 
in the survey (4,261 participants, response 67%) have been described in detail elsewhere49. A total of 
3,080 subjects participated in a follow-up examination of S4 in 2006/08 (KORA F4). For the genome-
wide KORA F4 study we selected 1,814 subjects of these participants. Informed consent has been 
given. The local ethical committee has approved the study. The KORA S3 and S4 samples do not 
overlap. In this study 1709 of these participants with blood pressure measurements were analysed.  
Blood pressure was measured using a OMRON  HEM-705CP machine in the seated position at the 
first examination cycle.  
Three measurements were taken at least three minutes apart and the numbers entering the 
database were the mean of the last two measurements. 
LBC1921/1936 
The LBC1921 cohort consists of 550 relatively healthy individuals, 316 females and 234 males, 
assessed on cognitive and medical traits at 79 years of age. They were born in 1921, most took part 
in the Scottish Mental Survey of 1932, and almost all lived independently in the Lothian region 
(Edinburgh City and surrounding area) in Scotland. When tested, the sample had a mean age of 79.1 
years (SD = 0.6). A full description of participant recruitment and testing can be found elsewhere50. 
The LBC1936 consists of 1,091 relatively healthy individuals assessed on cognitive and medical traits 
at 70 years of age. They were born in 1936, most took part in the Scottish Mental Survey of 1947, 
and almost all lived independently in the Lothian region of Scotland.  The sample of 548 men and 
543 women had a mean age 69.6 years (SD = 0.8).  A full description of participant recruitment and 
testing can be found elsewhere51. Ethics permission for the study was obtained from the Multi-
Centre Research Ethics Committee for Scotland (MREC/01/0/56) and from Lothian Research Ethics 
Committee (LBC1936: LREC/2003/2/29 and LBC1921: LREC/1998/4/183). The research was carried 
out in compliance with the Helsinki Declaration. All subjects gave written, informed consent. 
In LBC1921, blood pressure was measured once in a sitting position. In LBC1936, blood pressure was 
measured three times in a sitting position using the B026 Omron 705IT monitor. Individuals were 
excluded with the following criteria: recognized myocardial infarction, heart failure or coronary 
artery diseases. 
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LifeLines 
The LifeLines Cohort Study is a multi-disciplinary prospective population-based cohort study 
examining in a unique three-generation design the health and health-related behaviours of 165,000 
persons living in the North East region of The Netherlands. It employs a broad range of investigative 
procedures in assessing the biomedical, socio-demographic, behavioural, physical and psychological 
factors which contribute to the health and disease of the general population, with a special focus on 
multimorbidity. In addition, the LifeLines project comprises a number of cross-sectional sub-studies 
which investigate specific age-related conditions. These include investigations into metabolic and 
hormonal diseases, including obesity, cardiovascular and renal diseases, pulmonary diseases and 
allergy, cognitive function and depression, and musculoskeletal conditions. All survey participants 
are between 18 and 90 years old at the time of enrollment. Recruitment has been going on since the 
end of 2006, and until August 2010 over 30000 participants have been included.  
At the baseline examination, the participants in the study have been asked to fill in a questionnaire 
(on paper or online) before the first visit. During the first and second visit, the first or second part of 
the questionnaire, respectively, are checked for completeness, a number of investigations are 
conducted and blood and urine samples are taken. In the first visit to the LifeLines’ study center,  
trained technicians measure subjects’ systolic blood pressure, diastolic blood pressure, mean arterial 
pressure, and pulse rate, in every minute for a period of 10 minutes using a DINAMAP Monitor i.e. 
10 measures for each of the indices. The reported level for each of the blood pressure indices is an 
average estimate of all the 10 corresponding measures. 
LOLIPOP 
The LOndon LIfe Sciences POPulation study is an ongoing population-based cohort study of ~30,000 
individuals (18,000 Indian Asians and 12,000 European white men and women), aged 35-75 years 
and recruited from the lists of 58 general practitioners in West London, United Kingdom52,53. Blood 
pressure was measured using an Omron 705CP sphygmomanometer (mean of 3 measurements) 
with the subject seated. For the European ancestry validation stage of the present study, lookups 
were performed in 3 subgroups of European White (EW) ancestry that had been genotyped using 3 
GWAS platforms - LOLIPOP (EW_A), LOLIPOP (EW_P) and LOLIPOP (EW_610) - comprising in total 
1,603 individuals. For the South Asian ancestry replication stage of the present study, we used 
genotype data from 7 SNPs that had been genotyped in 12,900 individuals during previous work 6, 
and complemented these with lookups for 22 SNPs in 2 subgroups of Indian Asian ancestry that had 
been genotyped using 2 GWAS platforms - LOLIPOP (IA317) and LOLIPOP (IA610) - comprising in 
total 8,688 individuals. Analyses in GWAS datasets were adjusted for ancestry principal components, 
and analyses in the larger IA sample were adjusted for self-reported religion. 
MESA 
The Multi-Ethnic Study of Atherosclerosis investigation is a population-based study of 6,814 men and 
women age 45 to 85 years, without clinical cardiovascular disease, recruited from six United States 
communities (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles County, CA; northern 
Manhattan, NY; and St. Paul, MN). The main objective of MESA is to determine the characteristics of 
subclinical cardiovascular disease and its progression. Sampling and recruitment procedures have 
been previously described in detail54. Adults with symptoms or history of medical or surgical 
treatment for cardiovascular disease were excluded. During the recruitment process, potential 
participants were asked about their race/ethnicity. Self-reported ethnicity was used to classify 
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participants into groups55. After a 5-min rest BP was measured three times at 1 minute intervals 
using a Dinamap PRO 100 automated oscillometric device (Critikon, Tampa, FL) with the subject in a 
seated and the average of the second and third BP measurements was used in the analysis.  
MICROS 
The Micro-Isolates in South Tyrol (MICROS, EUROSPAN) study  
(http://www.biomedcentral.com/1471-2350/8/29) is part of the genomic health care program  
'GenNova' and was carried out in three villages of the Val Venosta on the populations of  Stelvio, 
Vallelunga and Martello. This study was an extensive survey carried out in South Tyrol (Italy) in the 
period 2001-2003. Study participants were volunteers from three isolated villages located in the 
Italian Alps, in a German-speaking region bordering with Austria and Switzerland. Due to 
geographical, historical and political reasons, the entire region experienced a prolonged period of 
isolation from surrounding populations. The 1,096 participants included in this study are those which 
had both phenotypic and GWAS data available. Blood pressure was taken after 3 minutes rest and 3 
consecutive measurements were recorded on the right upper arm using an HEM-705CP (OMRON). 
The median for each person was used in the analysis. 
MIGen 
The Myocardial Infarction Genetics Consortium cohort is composed of a subset of the controls of a 
case-control study aimed at identifying genetic variants associated with early-onset myocardial 
infarction. Most of the controls are selected from population based cross-sectional or cohort studies 
and come from five different studies: Heart Attack Risk in Puget Sound (Seattle, USA), REGICOR 
(Girona, Spain), MGH Premature Coronary Artery Disease Study (Boston, USA), FINRISK (Finland); 
Malmö Diet and Cancer Study (Malmö, Sweden). There is a minimal overlap of samples between the 
resources (N=30). For the majority of studies, blood pressure was measured twice using calibrated 
sphygmomanometers, in the seated position after at least 5 minutes of rest; the mean of the two 
measurements was used in the analysis. The first two principle components from an IBS analysis 
were used to adjust for potential population stratification. 
NESDA 
The Netherlands Study of Depression and Anxiety (NESDA)56, is a multi-centre study designed to 
examine the long-term course and consequences of depressive and anxiety disorders 
(http://www.nesda.nl). NESDA included both individuals with depressive and/or anxiety disorders 
and controls without psychiatric conditions. Inclusion criteria were age 18-65 years and self-reported 
western European ancestry, exclusion criteria were not being fluent in Dutch and having a primary 
diagnosis of another psychiatric condition (psychotic disorder, obsessive compulsive disorder, 
bipolar disorder, or severe substance use disorder).  
For all participants DNA was isolated from the baseline blood sample. Through funding from the 
fNIH GAIN program (www.fnih.gov/gain), whole genome scan analysis was conducted for 1859 
NESDA (1702 depressed cases and 157 controls) participants. A hundred subjects were excluded 
because of various quality control issues57. Additional exclusions were made based on disease 
history, medication use (e.g., 50 subjects using tricyclic antidepressants were excluded58) and 
phenotype leaving 1591 subjects in the final analysis dataset. Systolic blood pressure and diastolic 
blood pressure were measured twice using an OMRON IntelliSense Professional Digital Blood 
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Pressure Monitor, HEM-907XL (Omron Healthcare, Inc., Bannockburn, Illinois) during supine rest on 
the right arm, and were averaged over the two measurements58. 
 
NFBC1966 
The North Finland Birth Cohort of 1966 was designed to study factors affecting preterm birth, low 
birth weight, and subsequent morbidity and mortality (http://kelo.oulu.fi/NFBC/). The longitudinal 
data collection includes clinical examination and blood sampling at age 31 years, from which data in 
the current study are drawn. The attendees in the follow-up (71% response rate) were adequately 
representative of the original cohort59 as is the final study sample in the present analyses. Blood 
pressure was measured using a mercury sphygmomanometer, seated, from the right arm after 15 
minutes rest. The average of two readings taken 5 minutes apart was used for the analyses. Both 
questionnaire and national medication reimbursement data were used for anti-hypertensive 
medication information. 
NSPHS 
The Northern Swedish Population Health Study (EUROSPAN) represents a family-based prospective 
population study located in the parish of Karesuando, in the subartic region of the County of 
Norrbotten, Sweden. This parish has about 1,500 inhabitants, of whom 740 participated in the study. 
Historic population accounts show that there has been little immigration or other dramatic 
population changes in this area during the last 200 years. The study includes a comprehensive health 
investigation and collection of data on family structure, lifestyle, diet, medical history, and samples 
for clinical chemistry, RNA and DNA analyses. Blood pressure was taken once by the auscultatory 
method using a sphygmomanometer and a stethoscope. 
NTR  
Blood pressure data of Dutch twins and siblings participating in four different studies of the 
Netherlands Twin Register (NTR) were collected over the last decade60-63. These studies were 
approved by the medical ethical committee of the Free University of Amsterdam. Four triplets were 
included as pairs by discarding the data from the middle child. Study 1 was part of a project in which 
cardiovascular risk factors were studied in 160 twin families60. Addresses of twins living in and 
around Amsterdam were obtained from City Council population registries. Twins and both their 
biological parents were invited to participate. The age of the twins was between 14 and 21 years at 
the time of blood pressure measurement. Study 2 was also part of a cardiovascular risk factor 
project. Here, middle aged Dutch twins were recruited by a variety of means including 
advertisement in twin newsletters and through city councils61. A total of 213 families participated 
and twins were between 34 and 63 years old at time of measurement. In Study 3 blood pressure was 
measured in 261 extended Dutch twin families (twins and their siblings) who took part in a study of 
cognition and brain function62. The age of the subjects ranged between 14 and 71 years at time of 
measurement, with a somewhat bimodal distribution. Study 4 was a project studying the genetics of 
anxious-depression and cardiovascular risk factors63. Twins and siblings from the NTR were invited 
and 792 subjects from 339 families agreed to participate. The age of twins and siblings ranged 
between 17 and 81 years at the time of blood pressure measurement. 
Blood pressure measurements were done using brachial cuff measurements on the non-dominant 
arm by an automated Dynamap 845 recorder in the laboratory or by an ambulatory monitoring 
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device (Spacelabs 90207)64. The laboratory measurements were obtained with subjects sitting 
quietly for periods varying from 3 to 8 minutes. A mean of 3 to 6 BP measurements was taken as the 
BP resting value. In the ambulatory BP study the mean of all evening measurements when subjects 
were seated calmly was taken as the resting value (the mean number of measurements was 3.8, 
ranging from 1 to 10 per subject). The observed BP values in all four studies were corrected for the 
use of antihypertensive medication64,65. If subjects were taking antihypertensive medication at the 
time of measurement a correction of +14 mmHg for SBP and +10 mmHg for DBP was made for the 
laboratory studies. For the ambulatory study, the correction was drug class specific, but average 
values were close to +14 mmHg for SBP and +10 mmHg for DBP. From these corrected values, the PP 
value was calculated by subtracting DBP from SBP. 
ORCADES 
The Orkney Complex Disease Study (ORCADES) is an ongoing family-based cross-sectional study in 
the isolated Scottish archipelago of Orkney. Genetic diversity in this population is decreased 
compared to Mainland Scotland, consistent with the high levels of endogamy historically. Data for 
participants from a subgroup of ten islands were used for this analysis. Fasting blood samples were 
collected and over 200 health-related phenotypes and environmental exposures were measured in 
each individual. BP was recorded twice five minutes apart using a calibrated OMRON digital 
Sphygmomanometer, after at least 10 minutes of supine rest; the mean of the readings was used for 
the analyses. 
PROCARDIS 
The Precocious Coronary Artery Disease study (PROCARDIS) (www.procardis.org) is a European 
consortium investigating the genetics of precocious coronary artery disease (CAD) in German, Italian, 
Swedish, and British CAD patients and controls66. Country of origin was a covariate in all analyses. 
The controls were included in this study; these had no personal history of CAD, hypertension, or 
diabetes. Blood pressure was measured twice using various sphygmomanometers, in the seated 
position after at least 5 minutes of rest; the mean of the two measurements was used. 
PROSPER/PHASE 
All data come from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). A detailed 
description of the study has been published elsewhere67,68. PROSPER was a prospective multicenter 
randomized placebo-controlled trial to assess whether treatment with pravastatin diminishes the 
risk of major vascular events in elderly. Between December 1997 and May 1999, we screened and 
enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men and 
women aged 70-82 years were recruited if they had pre-existing vascular disease or increased risk of 
such disease because of smoking, hypertension, or diabetes. A total number of 5804 subjects were 
randomly assigned to pravastatin or placebo. A large number of prospective tests were performed 
including Biobank tests and cognitive function measurements. Blood pressure was measured in all 
subjects during the trial every 3 months by a standardized technique using Omron M4 
sphygmomanometers (Omron Healthcare Inc, Bannockburn, Illinois). A whole genome wide 
screening has been performed in the sequential PHASE project with the use of the Illumina 660K 
beadchip.  
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RS-I, RS-II and RS-III  
The Rotterdam Study I (RS-I), Rotterdam Study II (RS-II) and Rotterdam Study III (RS-III) are 
prospective population-based cohort studies; the RS-I comprises 7,983 subjects aged 55 years or 
older. Participants completed an interview at home and at the research centre, where participants 
were subsequently examined. Baseline data were collected between 1990 and 1993. In 1999, 
inhabitants who turned 55 years of age or moved into the study district since the start of the study 
were invited to participate in an extension of the RS (RS-II), 3,011 participated (67% response rate). 
In 2006 a further extension of the cohort was initiated in which 3,932 subjects were included (RSIII), 
aged 45 years and older, out of 6,057 subjects invited, living in the Ommoord district The rationale 
and design of the RS have been described in detail elsewhere69. At the research centre, we obtained 
two seated blood pressure measurements of the right brachial artery with a random zero 
sphygmomanometer. The mean of two consecutive measurements was used in association analyses. 
We excluded participants who were older than 85 years of age and those who had a history 
myocardial infarction or congestive heart failure, because of the impact of these conditions on blood 
pressure levels. 
SardiNIA 
The SardiNIA study is a longitudinal study examining age-related quantitative traits in individuals 
from the Ogliastra region of Sardinia, Italy70. The SardiNIA GWAS examined 4,305 related individuals 
(age >14 years), of whom 3,998 individuals were included in this study. Blood pressure was 
measured using a mercury sphygmomanometer; the average of the second and third reading was 
used for the analyses. 
SHIP 
The Study of Health In Pomerania is a population-based survey in West Pomerania, the North-East 
area of Germany71,72. A sample from the adult population aged 20 to 79 years was drawn based on 
population registries of cities and towns in the region. SHIP finally comprised 4,308 participants 
(corresponding to a final response rate of 68.8%). 3,310 individuals with GWAS data were included in 
this study. Blood pressure was measured three times, seated, after 5 minutes of rest, using a digital 
blood pressure monitor (HEM-705CP, Omron Corporation, Tokyo, Japan), after a rest period of 3 
minutes for each measurement. The mean of the second and third measurements was used in the 
analyses. 
SUVIMAX 
The SUpplementation en VItamines et Mineraux AntioXydants study is a longitudinal study 
performed on a national sample of healthy volunteers from France between 1996 and 2001. 1,823 
individuals, aged 35-65 years at baseline were included in this study73. Blood pressure was measured 
using a mercury sphygmomanometer in the seated position; the average of three readings taken 
from the first examination (1996) was used in the analysis. 
TwinsUK 
The TwinsUK Study comprises a sample of healthy female whites recruited through the TwinsUK 
registry in London (http://www.twin-research.ac.uk/indexscience.html). All participants were 
recruited from the general population without presence or interest in any particular disease or trait 
through national media campaigns. One of each twin pair was selected, with ages ranging from 18 to 
76 years. Blood pressure was measured using an Omron HEM-907 machine, seated. Three readings 
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were taken, the first was discarded and the average of the other two was used in the analyses. In the 
GWAS discovery (stage 0) data from 873 Twins UK participants was used (TwinsUK). During the study 
data from a further 2,163 independent individuals from study became available for analyses 
(TwinsUK2), which were used for lookups in stage 3 validation. 
YFS 
Cardiovascular risk in Young Finns Study was set up to determine the contribution of childhood 
lifestyle, biological, and psychological measures to the risk of cardiovascular diseases in adulthood. 
In 1980, over 3,500 children and adolescents from all over Finland participated in the baseline study. 
Thereafter these subjects were followed up with several examinations including comprehensive risk 
factor assessments. The 27-year follow-up was performed in 2007 and the blood pressure 
measurements at this time point were used for this study. Blood pressure was measured by nursing 
staff three times using a random-zero sphygmomanometer, the average of the three measurements 
were taken. Individuals were excluded if BMI, systolic or diastolic blood pressure measurements 
were missing or genotype data. 
WGHS 
The Women’s Genome Health Study (WGHS) is a prospective cohort of female North American 
health care professionals representing participants in the Women’s Health Study (WHS) trial who 
provided a blood sample at baseline and consent for blood-based analyses. Participants in the WHS 
were 45 years or older at enrolment and free of cardiovascular disease, cancer or other major 
chronic illness. For the primary WHS endpoints of cardiovascular disease, full medical records were 
obtained for reported endpoints and reviewed by an endpoints committee of physicians unaware of 
randomized treatment assignment. The current data are derived from 23,294 WGHS participants for 
whom whole genome genotype information was available at the time of analysis and for whom self-
reported European ancestry could be confirmed by multidimensional scaling analysis of 1,443 
ancestry informative markers in PLINK v. 1.06. Baseline BP in the WGHS was ascertained by a self-
reported questionnaire, an approach which has been validated in the WGHS demographic, namely 
female health care professionals74-76. Questionnaires recorded systolic blood pressure in 9 categories 
(<110, 110-119, 120-129, 130-139, 140-149, 150-159, 160-169, 170-179, =180 mmHg), and diastolic 
blood pressure in 7 categories (<65, 65-74, 75-84, 85-89, 90-94, 95-104, =105 mmHg). The midpoint 
of each category was used for analysis. Hypertension was defined as a history of physician-diagnosed 
HTN and ongoing HTN treatment, or SBP = 140 or DBP = 90 mmHg. To account for treatment effects, 
10 and 5 mmHg were added to the measured systolic and diastolic blood pressures respectively, if a 
participant was taking antihypertensive medication65. 
 
Outcome and eQTL studies 
AortaGen consortium 
Association statistics for pulse wave velocity (PWV) were obtained from the discovery meta-analysis 
of the  AortaGen Consortium (n=20,634), including 9 cohort studies that completed genome-wide 
genotyping and had measured CFPWV plus 2 cohort studies that had measured CFPWV and collected 
DNA for replication genotyping. Six cohorts, AGES, FHS, ERF, RSI, RSII and Sardinia overlap the 
discovery resources studies here. Sex-specific standardized regression residual for 1000/CFPWV, 
adjusted for age, age2, height and weight were used for the within-cohort association analyses, using 
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an additive gene-dose model. Results were combined across cohorts using a standard inverse 
variance weighted meta-analysis. During meta-analysis, results were filtered for weighted mean 
minor allele frequency <0.01 and the genomic control parameters were calculated to adjust each 
study. After meta-analysis, the genomic control parameter was recalculated to adjust for among-
study heterogeneity. 
C4D Consortium (CAD)  
The C4D consortium comprises CHD cases and controls of European origin from PROCARDIS and the 
Heart Protection Study (HPS) and of South Asian origin from the LOLIPOP and PROMIS studies. Data 
analysed with respect to risk of CHD all relate to the European origin participants from PROCARDIS 
and HPS. The PROCARDIS study included 5,720 cases of CHD (74.9% male, 80.4% myocardial 
infarction) and 1,684 controls recruited from Germany, Italy, Sweden and the UK. The controls were 
supplemented with N=2697 unselected individuals provided from the National Blood Service and 
used as common controls by the WTCCC. Many of the PROCARDIS cases are related to each other, 
and familial clustering was accounted for by using robust sandwich estimation of the variance, using 
Stata version 10. The HPS included 2704 CHD cases included in the HPS trial77 and 2887 controls 
from the 1958 Birth Cohort. The HPS was a large clinical trial of patients with either (i) CAD (ie, MI, 
unstable or stable angina, coronary artery bypass grafting, or angioplasty); or (ii) occlusive disease of 
non-coronary arteries (ie, stroke, leg artery stenosis; or (iii) diabetes mellitus; or (iv) treated 
hypertension (if also male and aged 65 or older). A total of 20,536 individuals (15,454 men and 5,082 
women) were recruited. Previous MI was reported by 8,510, some other history of CAD by 4,876, 
and no history of CAD by 7,150. Among the 13,386 with known CAD, 1,460 had cerebrovascular 
disease, 4,047 had peripheral arterial disease, and 1,981 had diabetes mellitus. GWAS genotyping 
was performed for a random sample of 4,000 participants with sufficient DNA and complete 
phenotypic information, and of these there were 2,704 CAD cases after quality control exclusions.  
 
Cardiogenics  
The Cardiogenics study included 758 individuals, including 363 patients with coronary artery disease 
(CAD) or myocardial infarction (MI) and 395 healthy individuals of European descent recruited in five 
centres within the Cardiogenics consortium (http://www.cardiogenics.eu). Healthy individuals were 
recruited in Cambridge (UK). CAD/MI patients (n=459) were recruited in Leicester (n=161), Lübeck 
(n=102), Regensburg (n=122) and Paris (n=74). The study was approved by the Institutional Ethical 
Committee of each participating centre. Blood samples (30ml) from fasting subjects were collected 
into EDTA and monocytes were isolated with CD14 micro beads using AutoMAcs/AutoMacs Pro 
(Miltenyi) according to the manufacturer’s instructions. Monocyte purity was measured as the 
percentage of CD14+ve cells analyzed by flow cytometry. Isolated monocytes were lysed in Trizol 
and RNA was extracted in chloroform and ethanol, washed in RNeasy columns (Qiagen) and 
incubated with DNase 1 before extracting in RNase-free water. RNA was quantified by the 
NanodropÒ method. Genomic DNA was extracted from peripheral blood monocytes by standard 
procedures (Qiagen) and sent to the Sanger Institute for genotyping. Gene expression profiling was 
performed using the Illumina’s Human Ref-8 Sentrix Bead Chip arrays (Illumina Inc., San Diego, CA) 
containing 24,516 probes corresponding to 18,311 distinct genes and 21,793 Ref Seq annotated 
71 
 
transcripts. mRNA was amplified and labelled using the Illumina Total Prep RNA Amplification Kit 
(Ambion, Inc., Austin, TX). After hybridization, Array images were scanned using the Illumina 
BeadArray Reader and probe intensities were extracted using the Gene expression module (version 
3.3.8) of the Illumina’s Bead Studio software (version 3.1.30). Raw intensities were processed in R 
statistical environment using the Lumi and beadarray packages. All array outliers were excluded and 
only arrays with high concordance in terms of gene expression measures (pairwise Spearman 
correlation coefficients within each cell type >0.85) were included in the analyses. After data quality 
control, 849 monocyte RNA samples were available for statistical analyses. Whole-genome 
genotyping was carried out using two arrays, the Sentrix Human Custom 1.2M array (1,115,839 SNPs 
and 80,128 CNVs) and the Human 610 Quad Custom array (594,398 SNP s and 66,049 CNVs) 
(Illumina). After filtering, which was based on sample call rate, ancestry, duplications and genetic 
relatedness; 758 were used for further analyses. Subsequent filtering removed SNPs if they had (i) a 
per-SNP call rate lower than 95% in cases or controls on the two arrays, and/or (ii) a minor allele 
frequency (MAF) of 1% in cases or in controls and/or (iii) a MAF in controls generated using the 
Illumina 1.2 M or in those generated on the 670k array and/or (iv) a significant deviation from 
Hardy-Weinberg equilibrium in the controls (P < 10-5). Furthermore, all SNPs on the Y and 
mitochondrial chromosomes as well as CNV markers were excluded from statistical analysis. After 
per-SNP data quality control, 522,603 SNPs represented on the two arrays and that passed the 
quality control, were used for further analyses. 
CARDIoGRAM (CAD)  
The Coronary ARtery DIsease Genome-wide Replication And Meta-analysis (CARDIoGRAM) 
consortium combines data from 14 GWAS, all published and several unpublished, in individuals with 
European ancestry including >22,000 cases with CAD and/or MI and >60,000 controls, and unifies 
samples from Atherosclerotic Disease VAscular functioN and genetiC Epidemiology study, CADomics, 
Cohorts for Heart and Aging Research in Genomic Epidemiology, deCODE, the German Myocardial 
Infarction Family Studies I, II, and III, Ludwigshafen Risk and Cardiovascular Heath 
Study/AtheroRemo, MedStar, Myocardial Infarction Genetics Consortium, Ottawa Heart Genomics 
Study, PennCath, and the Wellcome Trust Case Control Consortium. These studies have a case-
control design or are prospective cohort studies both having detailed phenotyping for CAD and/or 
MI as previously described78. Control subjects have been derived from population-based studies in 
most investigations. For all of the participating studies, genome-wide scans were performed in the 
years 2006-2009 using either Affymetrix or Illumina platforms followed by imputation of genotypes 
in most studies. Statistical methods have been standardized across the studies, and an analysis 
platform has been created to allow summarized analyses on CAD, MI, and related phenotypes. Data 
were combined across all studies (prevalent CAD case/control comparisons). Overall prevalence of 
MI within the CAD cases was 66%. 
CHARGE Consortium Heart Failure Working Group  
We obtained association data for SNPs of interest from the meta-analysis of 4 cohorts (ARIC, CHS, 
FHS and RS) with a total of 20,926 participants free of clinical heart failure at baseline, in whom 
2,526 incident heart failure events occurred during follow-up79. All cohorts included in the heart 
failure analysis are also included in PP and MAP-GWAS. Methods of ascertainment of incident heart 
failure events are discussed in detail by79. Briefly, potential events were identified during follow-up 
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using self-report, administrative data or in-person examinations, mostly validated by review of the 
medical data by a physician using published criteria79. Cox proportional hazards regression models 
were used for within-cohort analyses of the association between each SNP and time to incident 
heart failure, adjusting for sex and age. Results of individual cohorts were meta-analyzed using 
inverse variance weighted fixed-effect meta-analysis.  
CKDGen  
Association statistics for estimated glomerular filtration rate (eGFR) were obtained from the 
discovery meta-analysis of the CKDGen consortium, described previously80. eGFR was calculated 
from calibrated creatinine using the 4-variable MDRD Study equation. The discovery analysis for 
these phenotypes combined data from 20 cohorts with total sample size N=67,093. 14 of the 
cohorts: AGES, Amish, ARIC, BLSA, CHS, 1300 samples from ERF, FHS, KORA F3, MICROS, ORCADES, 
RS, RSII, SHIP and Vis, with total N=39,361, overlap the discovery cohorts studied here. Association 
statistics for dichotomous chronic kidney disease (CKD), urinary albumin/creatinine ratio (UACR), 
and dichotomous microalbuminuria, were obtained in collaboration with the CKDGen consortium by 
querying their datasets. CKD was defined as eGFR <60 ml/min/1.73m2, in the same set of samples in 
which eGFR was studied. The discovery analysis for urinary albumin/creatinine phenotypes 
combined data from 12 cohorts with total sample size N=31,580. 12 of the cohorts, Amish, ARIC, 
BLSA, CHS, CoLaus, EPIC, Fenland, FHS, KORA F3, MICROS, NSPHS, and SHIP, with total N=30,342, 
overlap those studied here. Microalbuminuria was defined as UACR >25mg/g [women] or >17 mg/g 
[men]. For CKD there were 5,807 cases and 61,286 controls available. For microalbuminuria 3,698 
cases and 27,882 controls were used. eGFR and urinary albumin/creatinine ratio were (natural) log 
transformed prior to analysis. Within-cohort association analyses regressed phenotype onto 
genotype using an additive genetic model with age and sex as covariates, using linear regression for 
continuous phenotypes and logistic regression for dichotomous phenotypes. Family-based methods 
were used where relevant. Results were combined across cohorts using an inverse variance 
weighted meta-analysis.  
DECODE 
Hypertension cases are composed of (1) self-reported hypertension (2) received the diagnosis of 
hypertension at discharge from the Landspitali University Hospital, Reykjavik or (3) attended the 
hypertemsion medical clinic at Landspitali University Hospital. The controls in the study consist 
of individuals from other ongoing genetic studies at deCODE. All individuals diagnosed with other 
cardiovascular diseases and hypertension were excluded from the control group.  All hypertension 
case and control samples were directly genotyped with the Illumina HumanHap300/CNV370 chips. 
Only SNPs present on both chips were included in the analysis and SNPs were excluded if they had (i) 
yield lower than 95% in cases or controls, (ii) minor allele frequency less than 1% in the population, 
or (iii) showed significant deviation from Hardy-Weinberg equilibrium in the controls (P < 0.001). All 
samples with a call rate below 98% were excluded from the analysis. Of the 40,000 that have 
currently been directly typed with Illumina HumanHap300/CNV370 chip at deCODE, 1000 individuals 
were genotyped with the Illumina Human1M-Duo chip and the Metabochip and the longe-range 
phased haplotypes that have been determined for the 40,000 individuals were used for the 
imputation of the Illumina Human1M-Duo chip and the Metabochip data to the hypertension cases 
and controls81. For the imputation of the HapMap v22 dataset to the hypertension case control set 
the IMPUTE model was used2. 
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EchoGen 
Association statistics for left ventricular (LV) wall thickness and LV mass were obtained from the 
discovery meta-analysis described previously82. The discovery analysis for this study combined data 
from 5 cohorts with total sample size N=12,612. Four of the cohorts CHS, RS, KORA F3, FHS, with 
total N=9,312, overlap those studied here. 
Subjects underwent routine transthoracic echocardiography, and methodology for measurements of 
LV dimensions, and calculations of mass and wall thickness, are given in detail by82. Within-cohort 
association analyses regressed LV mass and LV wall thickness onto additively coded (expected) 
genotype dose, with age, sex, height and weight as covariates, using linear regression (with random 
effects to account for relatedness where necessary). Results were combined across cohorts using an 
inverse variance weighted meta-analysis. 
KidneyGen consortium  
Association statistics for serum creatinine were obtained from the discovery meta-analysis of the 
KidneyGen consortium, described previously83. The discovery analysis for this study combined data 
from 9 cohorts, with total sample size N=23,812. Six cohorts, CoLaus, SardiNIA, 873 samples from 
TwinsUK, Fenland, InCHIANTI, NFBC1966, with total sample size N=17,699, overlap the discovery 
resource studied here. Serum creatinine concentrations were log10 transformed prior to analysis. 
Within-cohort association analyses were linear regressions of transformed serum creatinine on 
genotype, using an additive genetic model with age, sex and ancestry principal components as 
covariates. Results were combined across cohorts using a standard inverse variance weighted 
metaanalysis. Effect sizes were converted to a natural log transformed scale for presentation in 
Table 2 and Suppl. Table 11, for comparability with other phenotypes.  
NEURO-CHARGE (stroke)  
Association statistics for risk of incident stroke were obtained from the discovery metaanalysis of the 
CHARGE consortium, described previously84. The discovery analysis for these phenotypes combined 
data from 4 cohorts with total sample size N=19,602, of which there is a 100% overlap the ICBP-
GWAS4 discovery samples. For the stroke analysis, individuals who were stroke-free at recruitment 
were followed up for an average of 11 years, and there were 1544 incident strokes (of which 1164 
were ischemic strokes). The association analysis was a survival (time-to-event) analysis using a 
proportional hazards model, adjusted for age and sex as covariates.  
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concept/design: D.P.S. Phenotype data acquisition/QC: D.P.S. Genotype data acquisition/QC: 
W.L.McA. Data analysis: D.Hadley, D.P.S. 
 
Busselton Health Study (BHS) Study concept/design: L.J.P. Phenotype data acquisition/QC: J.P.B., 
J.H. Genotype data acquisition/QC: J.P.B., R.J.W. Data analysis: W.A.M., L.J.P., R.J.W. 
 
CardioGram: Study concept/design: CardioGram Consortium, N.J.S. Phenotype data 
acquisition/QC: CardioGram Consortium. Genotype data acquisition/QC: CardioGram Consortium. 
Data analysis: CardioGram Consortium. 
 
C4D Consortium Study concept/design: R.Clarke, R.Collins Phenotype data acquisition/QC: 
R.Clarke, R.Collins, J.C.H. Genotype data acquisition/QC: J.C.H., H.O. Data analysis: J.C.H., H.O. 
Cardiovascular Health Study (CHS) Study concept/design: J.C.B., N.L.G., B.M.P., K.M.R., K.D.T. 
Phenotype data acquisition/ QC: B.M.P. Genotype data acquisition/QC: J.C.B., N.L.G., K.D.T. Data 
analysis: J.C.B., N.L.G., K.M.R. 
 
CHARGE Consortium Heart Failure Working Group Study concept/design: CHARGE Consortium 
Heart Failure Working Group, N.L.S. Phenotype data acquisition/QC: CHARGE Consortium Heart 
Failure Working Group. Genotype data acquisition/QC: CHARGE Consortium Heart Failure Working 
Group. Data analysis: CHARGE Consortium Heart Failure Working Group. 
For complete acknowledgments see Smith NL et al. Circ Cardiovasc Genet. 2010 Jun 1;3(3):256-66. 
 
CKDGen consortium Study concept/design: CKDGen Consortium Phenotype data 
acquisition/QC: CKDGen Consortium Genotype data acquisition/QC: CKDGen Consortium Data 
analysis: CKDGen Consortium 
 
Cohorte Lausannoise (CoLaus) Study concept/design: V.M., P.Vollenweider, G.Waeber. Phenotype 
data acquisition/ QC: M.Bochud, V.M., P.Vollenweider Genotype data acquisition/QC: V.M., 
P.Vollenweider, Data analysis: S.Bergmann, M.Bochud, T.J.  
 
Coronary ARtery Disease Genome-wide Replication And Meta-analysis consortium (CARDIoGRAM) 
Study concept/design: CARDIoGRAM consortium Phenotype data acquisition/ QC: CARDIoGRAM 
consortium Genotype data acquisition/QC: CARDIoGRAM consortium Data analysis: CARDIoGRAM 
consortium 
CROATIA-Korcula Study concept/design: C.H. Phenotype data acquisition/ QC: C.H., O.P. Genotype 
data acquisition/QC: C.H., O.P. Data analysis: C.H., O.P. 
 
CROATIA-Split Study concept/design: M.Boban, I.R.  Phenotype data acquisition/ QC: M.Boban, I.R.  
Genotype data acquisition/QC: I.R. Data analysis: C.H. 
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CROATIA-Vis Study concept/design: A.F.W. Phenotype data acquisition/ QC: Genotype data 
acquisition/QC: V.V. Data analysis: V.V. 
 
DeCode Genetics:  H.H., K.S., G.T., U.T. 
Diabetes Genetics Initiative (DGI controls) Study concept/design: D.A., L.G., C.N-C. Phenotype data 
acquisition/ QC: L.G., C.N-C. Genotype data acquisition/QC: D.A., B.F.V. Data analysis: P.A., C.N-C., 
B.F.V. 
 
EchoGen Consortium Study concept/design: EchoGen Consortium. Phenotype data 
acquisition/QC: EchoGen Consortium.  Genotype data acquisition/QC: EchoGen Consortium.  Data 
analysis: EchoGen Consortium, J.F.F.  
For complete acknowledgments see Vasan RS et al. JAMA. 2009 Jul 8;302(2):168-78. 
 
ENGAGE: J.E., I.R.K., M.P. 
 
Estonian Genome Center, University of Tartu (EGCUT) Study concept/design: H.A., A.M. Phenotype 
data acquisition/ QC: H.A., A.K., A.M., M-L.T. Genotype data acquisition/QC:T.E., T.H. Data analysis: 
T.E., T.H. 
 
European Prospective Investigation of Cancer (EPIC) Norfolk Study concept/design: K-T.K. 
Phenotype data acquisition/ QC: N.J.W. Genotype data acquisition/QC: N.J.W. Data analysis: I.B., 
R.J.F.L., N.J.W., J.H.Z. 
 
ERF Study (EUROSPAN) Study concept/design: B.A.O. Phenotype data acquisition/ QC: Genotype 
data acquisition/QC: Data analysis: A.C.J.W.J., Y.A. 
 
Fenland study  Study concept/design: N.J.W. Phenotype data acquisition/ QC: N.J.W. Genotype data 
acquisition/QC: R.J.F.L., J.Luan, N.J.W. Data analysis: R.J.F.L, J.Luan. 
 
Framingham Heart Study (FHS) Phenotype data acquisition/ QC: S.-J.H., M.G.L., D.L., R.S.V., T.J.W.  
Genotype data acquisition/QC: S.-J.H., M.G.L. Data analysis: S.-J.H., M.G.L. 
 
Finland-United States Investigation of NIDDM Genetics Study (FUSION) Study concept/design: 
M.Boehnke, F.S.C., R.N.B., J.T. Phenotype data acquisition/ QC: J.T. Genotype data acquisition/QC: 
F.S.C. Data analysis: A.U.J. 
 
INGI Carlantino (CARL) Cohort  Study concept/design: A.P.d’A., P.Gasparini. Phenotype data 
acquisition/ QC: A.F., F.F., P.Gasparini, S.U. Genotype data acquisition/QC: A.P.d’A. Data analysis: 
N.P. 
 
INGI Friuli Venezia Giulia cohort (INGI FVG) Study concept/design: A.P.d’A., P.Gasparini. Phenotype 
data acquisition/ QC: A.F., F.F., P.Gasparini, S.U. Genotype data acquisition/QC: A.P.d’A. Data 
analysis: N.P. 
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INGI-Val Borbera Study concept/design: Phenotype data acquisition/ QC: C.Masciullo, C.S., D.T. 
Genotype data acquisition/QC: C.Masciullo, C.S., D.T. Data analysis: T.C., G.P., C.S., D.T. 
 
Invecchiare in Chianti (InCHIANTI) study Study concept/design: S.Bandinelli., Y.M. Phenotype data 
acquisition/ QC: A.M.C. Genotype data acquisition/QC: A.S. Data analysis: 
 
KOoperative Gesundheitsforschung in der Region Augsburg (KORA S3) Study concept/design: C.G., 
M.Laan, E.O. Phenotype data acquisition/ QC: C.G. Genotype data acquisition/QC: C.G., M.Laan, E.O. 
Data analysis: S.E., S.S. 
 
KOoperative Gesundheitsforschung in der Region Augsburg  (KORA F4) Study concept/design: T.M, 
H-E.W. Phenotype data acquisition/ QC: A.D. Genotype data acquisition/QC: T.M, H-E.W. Data 
analysis: B.K. 
 
LifeLines Study concept/design: R.P.S., M.M.V. Phenotype data acquisition/ QC: M.M.V.  Genotype 
data acquisition/QC: B.Z.A. Data analysis: B.Z.A. 
 
London Life Sciences POPulation study (LOLIPOP) Study concept/design: J.C.C., P.E., J.S.K. 
Phenotype data acquisition/ QC: J.C.C., J.S.K., J.S. Genotype data acquisition/QC: J.C.C., J.S.K., J.S., 
W.Z. Data analysis: J.C.C., J.S.K., X.Li, J.S., W.Z. 
 
Lothian Birth Cohorts 1921 & 1936 (LBC1921/LBC1936) Study concept/design: I.J.D., J.M.S. 
Phenotype data acquisition/ QC: I.J.D., L.M.L., J.M.S. Genotype data acquisition/QC: G.D., I.J.D. Data 
analysis: L.M.L. 
 
Micro-isolates in South Tyrol (MICROS) study (EUROSPAN) Study concept/design: A.Pfeufer 
Phenotype data acquisition/ QC: M.Facheris, A.Pfeufer Genotype data acquisition/QC:  I.P. Data 
analysis: F.D-G.M. 
 
Multi-Ethnic Study of Atherosclerosis (MESA) Study concept/design: X.G., W.P. Phenotype data 
acquisition/ QC: X.G., W.P. Genotype data acquisition/QC: X.G. Data analysis: X.G., W.P. 
 
Myocardial Infarction Genetics Consortium (MIGen controls) Study concept/design: O.M., C.J.O., 
V.S., D.Siscovick. Phenotype data acquisition/ QC: G.L., O.M., C.J.O., V.S., D.Siscovick. Genotype data 
acquisition/QC: G.L., O.M., C.J.O., V.S., D.S. Data analysis: G.L. 
 
Netherlands Study of Depression and Anxiety (NESDA) Study concept/design: B.W.P., H.Snieder 
Phenotype data acquisition/ QC: X.Lu, I.M.N., B.W.P., H.Snieder Genotype data acquisition/QC: J.F., 
X.Lu, I.M.N., B.W.P., H.Snieder Data analysis: J.F., X.Lu. 
 
NEURO-CHARGE Consortium Study concept/design: M.Breteler M.Fornage Phenotype data 
acquisition/QC: M.Breteler, S.D., A.L.D., M.Fornage Data analysis: S.D., A.L.D., M.Fornage. 
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North Finland Birth Cohort of 1966 (NFBC 1966) Study concept/design: M-R.J, P.Z. Phenotype data 
acquisition/ QC: P.E., M-R.J., J.Laitinen, A.Pouta, P.Z.  Genotype data acquisition/QC: P.E., M-R.J., 
J.Laitinen, P.Z. Data analysis: P.F.O’R. 
 
Northern Swedish Population Health Study (NSPHS EUROSPAN) Study concept/design: U.B.G., 
S.E.H. Phenotype data acquisition/ QC: J.A.C., U.B.G., S.E.H., P.J.T. Genotype data acquisition/QC: 
J.P., P.J.T. Data analysis: J.A.C., W.I. 
 
Netherlands Twin Register (NTR) Study concept/design: D.I.B., E. J.C. deG. Phenotype data 
acquisition/ QC: D.I.B., E.J.C.deG., G.Willemsen. Genotype data acquisition/QC: D.I.B., E.J.C.deG., J-
J.H., G.Willemsen. Data analysis: J-J.H. 
 
Orkney Complex Disease Study (ORCADES EUROSPAN) Study concept/design: H.C., J.F.W.  
Phenotype data acquisition/ QC: S.H.W., J.F.W. Genotype data acquisition/QC: H.C., J.F.W. Data 
analysis: P.N., S.H.W., J.F.W. 
 
Precocious Coronary Artery Disease (PROCARDIS controls) study Study concept/design: M.Farrall, 
A.Hamsten, J.F.P., H.W.  Phenotype data acquisition/ QC: J.F.P. Genotype data acquisition/QC: A.G., 
J.F.P. Data analysis: M.Farrall, A.G., J.F.P. 
 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER/PHASE) Study concept/design: 
B.B., J.W.J., D.Stott. Phenotype data acquisition/ QC: D.Stott, S.T. Genotype data acquisition/QC: S.T. 
Data analysis: J.W.J., S.T.  
 
Rotterdam Study (RSI, RSII, RSIII) Study concept/design: A.Hofman, C. M.V., J.C.M.W. Phenotype 
data acquisition/ QC: F.U.S.M.R., E.J.G.S., C.M.V., G.C.V., J.C.M.W. Genotype data acquisition/QC: 
F.R., A.G.U. Data analysis: N.A., S.K., C.M.V., G.C.V. 
 
SardiNIA study Study concept/design: G.A., M.U. Phenotype data acquisition/ QC: M.O., M.U. 
Genotype data acquisition/QC: G.A. Data analysis: J.L.B-G. 
 
Study of Health in Pomerania (SHIP) Study concept/design: M.D., H.K.K., R.R., U.V. , H.V. Phenotype 
data acquisition/ QC: M.D., R.R., H.V. Genotype data acquisition/QC: H.K.K., U.V., H.V. Data analysis: 
U.V. 
 
Supplémentation en Vitamines et Minéraux Antioxydants study (SUVIMAX) Study concept/design: 
P.Gilan, S.Hercberg, P.M. Phenotype data acquisition/ QC: P.Gilan, M.Lathrop Genotype data 
acquisition/QC: S.Heath, M.Lathrop Data analysis: T.J., P.M. 
 
TwinsUK study Study concept/design: T.D.S. Phenotype data acquisition/ QC: T.D.S. Genotype data 
acquisition/QC: M.M., S-Y.S, N.S., F.Z. Data analysis: N.S., F.Z. 
 
Women’s Genome Health Study (WGHS) Study concept/design: P.M.R. Phenotype data acquisition/ 
QC: D.I.C., A.N.P. Genotype data acquisition/QC: P.M.R. Data analysis: D.I.C., L.M.R. 
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Cardiovascular risk in Young Finns Study (YFS) Study concept/design: M.K., T.L., O.T.R., J.V.  
Phenotype data acquisition/ QC: M.K., T.L., O.T.R., J.V. Genotype data acquisition/QC: M.K., T.L., 
O.T.R., J.V. Data analysis: T.L., O.T.R. 
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